<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility - Skalkidou, A - 2017 | Cochrane Library</title> <meta content="Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility - Skalkidou, A - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010931.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility - Skalkidou, A - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010931.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010931.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility" name="citation_title"/> <meta content="Alkistis Skalkidou" name="citation_author"/> <meta content="Uppsala University" name="citation_author_institution"/> <meta content="alkistis.skalkidou@kbh.uu.se" name="citation_author_email"/> <meta content="Theodoros N Sergentanis" name="citation_author"/> <meta content="Medical School, National and Kapodistrian University of Athens" name="citation_author_institution"/> <meta content="Spyros P Gialamas" name="citation_author"/> <meta content="Medical School, National and Kapodistrian University of Athens" name="citation_author_institution"/> <meta content="Marios K Georgakis" name="citation_author"/> <meta content="Medical School, National and Kapodistrian University of Athens" name="citation_author_institution"/> <meta content="Theodora Psaltopoulou" name="citation_author"/> <meta content="Medical School, National and Kapodistrian University of Athens" name="citation_author_institution"/> <meta content="Marialena Trivella" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Charalampos S Siristatidis" name="citation_author"/> <meta content="Medical School, National and Kapodistrian University of Athens" name="citation_author_institution"/> <meta content="Evangelos Evangelou" name="citation_author"/> <meta content="University of Ioannina Medical School" name="citation_author_institution"/> <meta content="Eleni Petridou" name="citation_author"/> <meta content="Medical School, National and Kapodistrian University of Athens" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD010931.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/03/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010931.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010931.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010931.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Case‐Control Studies; Chorionic Gonadotropin [administration &amp; dosage, adverse effects]; Clomiphene [administration &amp; dosage, *adverse effects]; Drug Therapy, Combination [adverse effects]; Endometrial Neoplasms [*chemically induced, epidemiology]; Fertility Agents, Female [administration &amp; dosage, *adverse effects]; Gonadotropin‐Releasing Hormone [administration &amp; dosage, adverse effects]; Gonadotropins [*adverse effects]; Infertility, Female [complications, *drug therapy]; Ovulation Induction; Retrospective Studies; Risk" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010931.pub2&amp;doi=10.1002/14651858.CD010931.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010931\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010931\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010931.pub2",title:"Risk of endometrial cancer in women treated with ovary\\u2010stimulating drugs for subfertility",firstPublishedDate:"Mar 25, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010931.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010931.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010931.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010931.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010931.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010931.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010931.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010931.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010931.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010931.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3134 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010931.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-sec-0096"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-sec-0090"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/appendices#CD010931-sec-0101"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/table_n/CD010931StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/table_n/CD010931StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Risk of endometrial cancer in women treated with ovary‐stimulating drugs for subfertility</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Alkistis Skalkidou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0003">Theodoros N Sergentanis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0004">Spyros P Gialamas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0005">Marios K Georgakis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0006">Theodora Psaltopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0007">Marialena Trivella</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0008">Charalampos S Siristatidis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0009">Evangelos Evangelou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information#CD010931-cr-0010">Eleni Petridou</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information/en#CD010931-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 March 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010931.pub2">https://doi.org/10.1002/14651858.CD010931.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010931-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010931-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010931-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010931-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010931-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010931-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010931-abs-0001" lang="en"> <section id="CD010931-sec-0001"> <h3 class="title" id="CD010931-sec-0001">Background</h3> <p>Medical treatment for subfertility principally involves the use of ovary‐stimulating agents, including selective oestrogen receptor modulators (SERMs), such as clomiphene citrate, gonadotropins, gonadotropin‐releasing hormone (GnRH) agonists and antagonists, as well as human chorionic gonadotropin. Ovary‐stimulating drugs may act directly or indirectly upon the endometrium (lining of the womb). Nulliparity and some causes of subfertility are recognized as risk factors for endometrial cancer. </p> </section> <section id="CD010931-sec-0002"> <h3 class="title" id="CD010931-sec-0002">Objectives</h3> <p>To evaluate the association between the use of ovary‐stimulating drugs for the treatment of subfertility and the risk of endometrial cancer. </p> </section> <section id="CD010931-sec-0003"> <h3 class="title" id="CD010931-sec-0003">Search methods</h3> <p>A search was performed in CENTRAL, MEDLINE (Ovid) and Embase (Ovid) databases up to July 2016, using a predefined search algorithm. A search in OpenGrey, ProQuest, ClinicalTrials.gov, ZETOC and reports of major conferences was also performed. We did not impose language and publication status restrictions. </p> </section> <section id="CD010931-sec-0004"> <h3 class="title" id="CD010931-sec-0004">Selection criteria</h3> <p>Cohort and case‐control studies reporting on the association between endometrial cancer and exposure to ovary‐stimulating drugs for subfertility in adult women were deemed eligible. </p> </section> <section id="CD010931-sec-0005"> <h3 class="title" id="CD010931-sec-0005">Data collection and analysis</h3> <p>Study characteristics and findings were extracted by review authors independently working in pairs. Inconsistency between studies was quantified by estimating I<sup>2</sup>. Random‐effects (RE) models were used to calculate pooled effect estimates. Separate analyses were performed, comparing treated subfertile women versus general population and/or unexposed subfertile women, to address the superimposition of subfertility as an independent risk factor for endometrial cancer. </p> </section> <section id="CD010931-sec-0006"> <h3 class="title" id="CD010931-sec-0006">Main results</h3> <p>Nineteen studies were eligible for inclusion (1,937,880 participants). Overall, the quality of evidence was very low, due to serious risk of bias and indirectness (non‐randomised studies (NRS), which was reflected on the GRADE assessment. </p> <p>Six eligible studies, including subfertile women, without a general population control group, found that exposure to any ovary‐stimulating drug was not associated with an increased risk of endometrial cancer (RR 0.96, 95% CI 0.67 to 1.37; 156,774 participants; very low quality evidence). Fifteen eligible studies, using a general population as the control group, found an increased risk after exposure to any ovary‐stimulating drug (RR 1.75, 95% CI 1.18 to 2.61; 1,762,829 participants; very low quality evidence). </p> <p>Five eligible studies, confined to subfertile women (92,849 participants), reported on exposure to clomiphene citrate; the pooled studies indicated a positive association ( RR 1.32; 95% CI 1.01 to 1.71; 88,618 participants; very low quality evidence), although only at high dosage (RR 1.69, 95% CI 1.07 to 2.68; two studies; 12,073 participants) and at a high number of cycles (RR 1.69, 95% CI 1.16 to 2.47; three studies; 13,757 participants). Four studies found an increased risk of endometrial cancer in subfertile women who required clomiphene citrate compared to a general population control group (RR 1.87, 95% CI 1.00 to 3.48; four studies, 19,614 participants; very low quality evidence). These data do not tell us whether the association is due to the underlying conditions requiring clomiphene or the treatment itself. </p> <p>Using unexposed subfertile women as controls, exposure to gonadotropins was associated with an increased risk of endometrial cancer (RR 1.55, 95% CI 1.03 to 2.34; four studies; 17,769 participants; very low quality evidence). The respective analysis of two studies (1595 participants) versus the general population found no difference in risk (RR 2.12, 95% CI 0.79 to 5.64: very low quality evidence). </p> <p>Exposure to a combination of clomiphene citrate and gonadotropins, compared to unexposed subfertile women, produced no difference in risk of endometrial cancer (RR 1.18, 95% CI 0.57 to 2.44; two studies; 6345 participants; very low quality evidence). However, when compared to the general population, an increased risk was found , suggesting that the key factor might be subfertility, rather than treatment (RR 2.99, 95% CI 1.53 to 5.86; three studies; 7789 participants; very low quality evidence). </p> </section> <section id="CD010931-sec-0007"> <h3 class="title" id="CD010931-sec-0007">Authors' conclusions</h3> <p>The synthesis of the currently available evidence does not allow us to draw robust conclusions, due to the very low quality of evidence. It seems that exposure to clomiphene citrate as an ovary‐stimulating drug in subfertile women is associated with increased risk of endometrial cancer, especially at doses greater than 2000 mg and high (more than 7) number of cycles. This may largely be due to underlying risk factors in women who need treatment with clomiphene citrate, such as polycystic ovary syndrome, rather than exposure to the drug itself. The evidence regarding exposure to gonadotropins was inconclusive. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010931-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010931-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010931-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010931-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010931-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010931-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010931-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010931-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010931-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010931-abs-0005" lang="en"> <h3>Risk of endometrial cancer in subfertile women undergoing ovarian stimulation</h3> <p><b>Background</b> <br/> For the treatment of subfertility (delay in becoming pregnant), several medications are used to stimulate ovulation ‐ the process of maturation and release of eggs from the ovaries. These drugs may also affect the endometrium, which is the layer of tissue lining of the womb (uterus). However, conditions that cause subfertility are known risk factors for endometrial cancer (cancer of the lining of the womb) while pregnancy and combined oral contraceptive pills have a protective effect, significantly reducing the risk of endometrial cancer. Separating causative effect of medicines used to treat subfertility from other underlying causes, which may increase the individual's risk of endometrial cancer, is therefore extremely challenging. </p> <p><b>The aim of the review</b> <br/> To find out whether the medicines used to stimulate ovulation increase the risk of endometrial cancer in women who need medical help to get pregnant. </p> <p><b>Key results</b> <br/> The evidence is current to July 2016. Nineteen studies, including 1,937,880 participants, were identified that compared the risk of developing cancer of the lining of the womb (endometrial cancer) in women exposed to ovary‐stimulating drugs versus either subfertile women not exposed to these drugs, or women from the general population. Overall, exposure to clomiphene citrate, mainly in high dosage and in repeated cycles, may be associated with an increased risk of developing endometrial cancer later in life. The evidence about the relationship between exposure to gonadotropins and endometrial cancer was less robust. It is not possible to say whether the increased risk is due to ovulation‐stimulating drug use or to the underlying cause of subfertility. </p> <p><b>Quality of the evidence</b> <br/> The quality of the evidence for the findings was very low, as the included studies had severe limitations and multiple differences in the way they were conducted. </p> <p><b>What are the conclusions?</b> <br/> Women who need treatment with clomiphene citrate should be aware that they are at increased risk of endometrial cancer, but this is largely due to underlying condition causing subfertility and it is not possible to assess the additional effect of clomiphene citrate, based on available data. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010931-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010931-sec-0096"></div> <h3 class="title" id="CD010931-sec-0097">Implications for practice</h3> <section id="CD010931-sec-0097"> <p>The available data was of very low quality and at significant risk of bias, since it is known that subfertile women have risk factors for endometrial cancer that are independent of treatment for subfertility. It seems that the exposure to clomiphene citrate as an ovary‐stimulating drug in subfertile women may be associated with an increased risk of endometrial cancer, especially at higher doses (more than 2000 mg) and higher number of cycles (7 or more cycles). Evidence regarding exposure to gonadotropins is even less conclusive. It is therefore difficult to give any certainty about the safety of subfertility treatments. Contemporary guidelines already recommend treatment with clomiphene citrate as the first line of treatment for up to 12 months only for women with World Health Organization Group II ovulation disorders (hypothalamic pituitary dysfunction), such as PCOS (<a href="./references#CD010931-bbs2-0055" title="National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London (UK): RCOG Press, 2013. [PUBMED: 25340218] ">NICE 2013</a>). These data should not prevent women from seeking treatment of subfertility, but they should be aware of their underlying increased risk of endometrial cancer and adopt lifestyle changes to reduce their risk, such as weight loss and adequate endometrial protection with progesterones, should they have oligomenorrhoea due to PCOS. </p> </section> <h3 class="title" id="CD010931-sec-0098">Implications for research</h3> <section id="CD010931-sec-0098"> <p>This systematic review points to the need for register‐based studies with the potential to span longer follow‐up periods, to provide detailed subfertility treatment history and adjustment for confounding factors, so as to avoid the additive effect of subfertility. Detailed analyses concerning histotypes, dose‐response effects and the potentially modifying role of parity, gravidity or age at first exposure seem warranted. Endometrial cancer is recognized as being a heterogenous disease, with different aetiologies for type I and type II tumours. Given that no studies have been undertaken assessing differences in the associations for ovary‐stimulating drugs between these two major groupings of tumours, future studies should bear this in mind. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010931-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010931-sec-0029"></div> <div class="table" id="CD010931-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Exposure to any ovary‐stimulating drugs for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to any ovary‐stimulating drug for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to any ovary‐stimulating drug for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.67 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156,774<br/> (6 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 100,000<br/> (74 to 163) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of high risk of bias.<br/> <sup>3</sup>Optimal information size (OIS) criterion not met (OIS = 499,938); however, the sample size was large. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Exposure to any ovary‐stimulating drugs for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to any ovary‐stimulating drug for subfertility<br/> <b>Comparison:</b> General population </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to any ovary‐stimulating drug for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75<br/> (1.18 to 2.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,762,829<br/> (15 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 100,000<br/> (62 to 138) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of high risk of bias.<br/> <sup>3</sup> Downgraded due to inconsistency of results (significant heterogeneity) and imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Exposure to clomiphene citrate for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/> (1.01 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92,849<br/> (5 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>524 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>691 per 100,000<br/> (530 to 894) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup> Optimal information size (OIS) criterion not met; however, the sample size was large. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Exposure to clomiphene citrate for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate for subfertility<br/> <b>Comparison:</b> General population </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.87<br/> (1.00 to 3.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,614<br/> (4 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>529 per 100,000<br/> (284 to 980) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup>Optimal information size (OIS) criterion not met. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Exposure to gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>undefined</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to gonadotropins for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.55<br/> (1.03 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17,769<br/> (4 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1291 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1987 per 100,000<br/> (1329 to 2970) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias in most studies and imprecise estimates in one study.<br/> <sup>3</sup> Optimal information size (OIS) not met. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Exposure to gonadotropins for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to gonadotropins for subfertility<br/> <b>Comparison:</b> General population </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.12<br/> (0.79 to 5.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1595<br/> (2 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1148 per 100,000<br/> (428 to 3054) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup>Downgraded because of risk of bias and imprecision.<br/> <sup>3</sup> Optimal information size (OIS) not met. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Exposure to clomiphene citrate and gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate and gonadotropins for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate and gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.57 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6345<br/> (2 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>579 per 100,000<br/> (279 to 1196) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup> Optimal information size (OIS) criterion not met. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Exposure to clomiphene citrate and gonadotropins for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate and gonadotropins for subfertility<br/> <b>Comparison:</b> General population 2.99 [1.53, 5.86] </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate and gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.99<br/> (1.53 to 5.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7789<br/> (3 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 100,000<br/> (150 to 401) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup> Optimal information size (OIS) not met; however, the sample size was large. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010931-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Exposure to GnRH analogues for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to GnRH analogues for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to GnRH analogs for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/> (0.65 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42,558<br/> (2 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>554 per 100,000<br/> (297 to 1039) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup>Optimal information size (OIS) criterion not met; however, the sample size was large </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010931-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010931-sec-0030"></div> <section id="CD010931-sec-0031"> <h3 class="title" id="CD010931-sec-0031">Description of the condition</h3> <p>Subfertility remains a key issue for modern societies in terms of the psychosocial well‐being of those involved, as well as the financial and public health burden (<a href="./references#CD010931-bbs2-0033" title="ChambersGM , ChapmanMG , GraysonN , ShanahanM , SullivanEA . Babies born after ART treatment cost more than non‐ART babies: a cost analysis of inpatient birth‐admission costs of singleton and multiple gestation pregnancies. Human Reproduction2007;22(12):3108‐15. ">Chambers 2007</a>; <a href="./references#CD010931-bbs2-0034" title="ChambersGM , HoangVP , IllingworthPJ . Socioeconomic disparities in access to ART treatment and the differential impact of a policy that increased consumer costs. Human Reproduction2013;28(11):3111‐7. ">Chambers 2013</a>). In the UK, subfertility has been defined as failure to conceive after regular unprotected sexual intercourse for one year in the absence of known reproductive pathology (<a href="./references#CD010931-bbs2-0055" title="National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London (UK): RCOG Press, 2013. [PUBMED: 25340218] ">NICE 2013</a>). The revised glossary published by the International Committee for Monitoring Assisted Reproductive Technology (ICMART), in collaboration with the World Health Organization (WHO) (<a href="./references#CD010931-bbs2-0068" title="Zegers‐HochschildF , AdamsonGD , DeMouzonJ , IshiharaO , MansourR , NygrenK , et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertility and Sterility2009;92(5):1520‐4. [PUBMED: 19828144] ">Zegers‐Hochschild 2009</a>), as well as the Practice Committee of the American Society for Reproductive Medicine (<a href="./references#CD010931-bbs2-0029" title="Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertility and Sterility2013;99(1):63. [PUBMED: 23095139] ">ASRM 2013</a>), also set the time interval for definition of subfertility at one year. </p> <p>Subfertility has several causes, with male partners' factors prevailing in about 30% of cases and female partners' factors in 50% of cases (<a href="./references#CD010931-bbs2-0036" title="Expert Group on Commissioning NHS Infertility Provision. Regulated fertility services: a commissioning aid. www.dh.gov.uk/publications (accessed 18 June 2009). ">DH 2009</a>). The most commonly identifiable female factors are ovulatory disorders, endometriosis (a condition characterized by painful menses and abnormal growth of endometrial tissue outside the uterus), pelvic adhesions (scar tissue), tubal blockage or other tubal abnormalities, and hyperprolactinaemia (increased blood levels of the hormone prolactin) (<a href="./references#CD010931-bbs2-0041" title="FritzM , SperoffL . Clinical Gynecologic Endocrinology and Infertility. Baltimore (USA): Lippincott Williams &amp; Wilkins, 2010. ">Fritz 2010</a>; <a href="./references#CD010931-bbs2-0066" title="KuohungW , HornsteinMD . Overview of infertility. www.uptodate.com/contents/overview‐of‐infertility?detectedLanguage=en&amp;source=search_result&amp;search=overview+of+infertility&amp;selectedTitle=1%7E150&amp;provider=noProvider (assessed 28 June 2013). ">UpToDate 2013</a>). </p> <p>Endometrial cancer (cancer of the lining of the womb) is a common cancer. In the USA, there is a 2.8% lifetime risk of endometrial cancer. Between 2009 and 2013, the number of new cases of endometrial cancer was 25.4 per 100,000 women per year; 4.5 per 100,000 women per year will die from the disease (<a href="./references#CD010931-bbs2-0060" title="Surveillance , Epidemiology and End Results Program. Statistics at a Glance. SEER Statistical Fact Sheets: Endometrial Cancer2016. ">SEER 2016</a>). Nulliparity is a recognised risk factor for endometrial cancer (<a href="./references#CD010931-bbs2-0032" title="CetinI , CozziV , AntonazzoP . Infertility as a cancer risk factor ‐ a review. Placenta2008;29 Suppl B:169‐77. ">Cetin 2008</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>), as are conditions associated with subfertility, such as polycystic ovary syndrome (a common endocrine system disorder among women of reproductive age frequently associated with high free adrogen levels and the presence of many growing follicles in the ovaries), diabetes and obesity (<a href="./references#CD010931-bbs2-0039" title="DiSaiaPJ , CreasmanWT . Clinical Gynecologic Oncology. 8th Edition. New York (USA): Mosby, Elsevier, 2012. ">DiSaia 2012</a>), and the impact of treatment for subfertility on the risk of endometrial cancer is also being explored (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>). Pregnancy and use of combined oral contraceptives are known to reduce the risk of endometrial cancer, both of which are less common in women with subfertility (<a href="./references#CD010931-bbs2-0032" title="CetinI , CozziV , AntonazzoP . Infertility as a cancer risk factor ‐ a review. Placenta2008;29 Suppl B:169‐77. ">Cetin 2008</a>; <a href="./references#CD010931-bbs2-0039" title="DiSaiaPJ , CreasmanWT . Clinical Gynecologic Oncology. 8th Edition. New York (USA): Mosby, Elsevier, 2012. ">DiSaia 2012</a>). These factors make differentiating causation and association extremely challenging. </p> </section> <section id="CD010931-sec-0032"> <h3 class="title" id="CD010931-sec-0032">Description of the intervention</h3> <p>Treatment for subfertility principally involves the use of fertility medication. Ovary‐stimulating drugs are predominantly used for the treatment of women suffering from the ovulation disorders, WHO Group I (hypothalamic pituitary failure) and Group II (hypothalamic pituitary dysfunction, predominantly polycystic ovary syndrome) (<a href="./references#CD010931-bbs2-0055" title="National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London (UK): RCOG Press, 2013. [PUBMED: 25340218] ">NICE 2013</a>). These agents can be used to induce ovulation in anovulatory women (anovulation refers to the non‐release of an oocyte during a menstrual cycle), but can also be implemented for controlled ovarian stimulation in women undergoing assisted reproduction. </p> <p>Commonly used agents and their uses are listed here:</p> <p> <ul id="CD010931-list-0001"> <li> <p>Selective oestrogen receptor modulators (SERMs), such as tamoxifen and clomiphene citrate, make up a class of compounds that act on oestrogen receptors (<a href="./references#CD010931-bbs2-0064" title="SteinerAZ , TerplanM , PaulsonRJ . Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta‐analysis. Human Reproduction2005;20(6):1511‐5. [PUBMED: 15845599] ">Steiner 2005</a>).These agents are used during the follicular phase (the first phase of the menstrual cycle before relase of the oocyte) to increase the serum concentration of gonadotropins, which stimulate the ovary and promote follicle (the organized aggregation of cells containing the oocyte) maturation and ovulation (<a href="./references#CD010931-bbs2-0050" title="KlipH , BurgerCW , KenemansP , VanLeeuwenFE . Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes and Control2000;11(4):319‐44. [PUBMED: 10843444] ">Klip 2000</a>); </p> </li> <li> <p>Gonadotropins (luteinising hormone (LH) and follicle‐stimulating hormone (FSH) that stimulate the ovaries may be used in their recombinant form (i.e. rFSH; produced in the laboratory from DNA coming from different sources) or as human menopausal gonadotropins (hMGs), which consist of LH and FSH extracted from the urine of menopausal women (<a href="./references#CD010931-bbs2-0055" title="National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London (UK): RCOG Press, 2013. [PUBMED: 25340218] ">NICE 2013</a>); </p> </li> <li> <p>Gonadotropin‐releasing hormone (GnRH) agonists (chemicals that mimic the hormone actions) and antagonists (chemicals that inhibit the hormone actions) are nearly always used in conjunction with gonadotropins. They facilitate cycle control during in vitro fertilisation (IVF) treatment (<a href="./references#CD010931-bbs2-0055" title="National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London (UK): RCOG Press, 2013. [PUBMED: 25340218] ">NICE 2013</a>); their inclusion in this review inherently encompasses their combination with hMG or FSH; </p> </li> <li> <p>Human chorionic gonadotropin (hCG), used intramuscularly, mimics the role of LH and induces ovulation or maturation of the oocytes (<a href="./references#CD010931-bbs2-0055" title="National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: assessment and treatment for people with fertility problems. London (UK): RCOG Press, 2013. [PUBMED: 25340218] ">NICE 2013</a>). </p> </li> </ul> </p> </section> <section id="CD010931-sec-0033"> <h3 class="title" id="CD010931-sec-0033">How the intervention might work</h3> <p>Fertility drugs raise the serum levels of endogenous gonadal hormones (estrogens and progesterone naturally produced by women) and gonadotropins and consequently increase the chance of multiple ovulations per menstrual cycle. Although the mechanisms that link fertility drugs to endometrial cancer risk are not completely clear (<a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>), it has been suggested that these agents result in prolonged exposure of the endometrium to 'unopposed' or high levels of oestrogen, hence raising the risk of endometrial cancer by increasing mitotic activity (cell division resulting in increasing number of cells) and DNA replication errors (<a href="./references#CD010931-bbs2-0027" title="AkhmedkhanovA , Zeleniuch‐JacquotteA , TonioloP . Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Annals of the New York Academy of Sciences2001;943:296‐315. [PUBMED: 11594550] ">Akhmedkhanov 2001</a>; <a href="./references#CD010931-bbs2-0030" title="AyhanA , SalmanMC , CelikH , DursunP , OzyuncuO , GultekinM . Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstetricia et Gynecologica Scandinavica2004;83(12):1104‐11. [PUBMED: 15548140] ">Ayhan 2004</a>). However, fertility drugs, by inducing ovulatory cycles and pregnancies, may also induce progesterone production, exerting potentially protective effects in terms of endometrial cancer risk. </p> <p>Specifically, fertility drugs provide the following effects.</p> <p> <ul id="CD010931-list-0002"> <li> <p>Selective oestrogen receptor modulators (SERMs, e.g. clomiphene citrate) are associated with a twofold to threefold increase in the mean oestradiol level, resulting in enhancement of ovulation during treated cycles, as well as an increase in progesterone levels (<a href="./references#CD010931-bbs2-0038" title="DickeyRP , HoltkampDE . Development, pharmacology and clinical experience with clomiphene citrate. Human Reproduction Update1996;2(6):483‐506. ">Dickey 1996</a>; <a href="./references#CD010931-bbs2-0063" title="SovinoH , Sir‐PetermannT , DevotoL . Clomiphene citrate and ovulation induction. Reproductive BioMedicine Online2002;4(3):303‐10. ">Sovino 2002</a>). Clomiphene citrate might also affect the risk of endometrial cancer by interacting directly with oestrogen receptors within the uterus (<a href="./references#CD010931-bbs2-0042" title="GoldsteinSR , SiddhantiS , CiacciaAV , PlouffeLJr . A pharmacological review of selective oestrogen receptor modulators. Human Reproduction Update2000;6(3):212‐24. ">Goldstein 2000</a>; <a href="./references#CD010931-bbs2-0054" title="NakamuraY , OnoM , YoshidaY , SuginoN , UedaK , KatoH . Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertility and Sterility1997;67(2):256‐60. [PUBMED: 9022599] ">Nakamura 1997</a>). Similarly, tamoxifen (<a href="./references#CD010931-bbs2-0031" title="BrownJ , FarquharC , BeckJ , BoothroydC , HughesE . Clomiphene and anti‐oestrogens for ovulation induction in PCOS. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD002249.pub4] ">Brown 2009</a>; <a href="./references#CD010931-bbs2-0037" title="DhaliwalLK , SuriV , GuptaKR , SahdevS . Tamoxifen: an alternative to clomiphene in women with polycystic ovary syndrome. Journal of Human Reproductive Sciences2011;4(2):76‐9. ">Dhaliwal 2011</a>) has been associated with an increased risk of endometrial cancer (<a href="./references#CD010931-bbs2-0065" title="SwerdlowAJ , JonesME , British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case‐control study. Journal of the National Cancer Institute2005;97(5):375‐84. ">Swerdlow 2005</a>). </p> </li> <li> <p>Treatment with hMG or FSH, as in IVF, may substantially increase the number of ovulations compared with that seen in untreated women (<a href="./references#CD010931-bbs2-0050" title="KlipH , BurgerCW , KenemansP , VanLeeuwenFE . Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes and Control2000;11(4):319‐44. [PUBMED: 10843444] ">Klip 2000</a>). </p> </li> <li> <p>hCG mimics the function of LH by initiating oocyte (female egg cell) maturation/ovulation (<a href="./references#CD010931-bbs2-0050" title="KlipH , BurgerCW , KenemansP , VanLeeuwenFE . Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes and Control2000;11(4):319‐44. [PUBMED: 10843444] ">Klip 2000</a>). </p> </li> <li> <p>GnRH modulates the endogenous pituitary release of LH and FSH and subsequent folliculogenesis (maturation of the ovarian follicle). GnRH agonists and antagonists are regularly used as an addition to the treatment of female subfertility (<a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0050" title="KlipH , BurgerCW , KenemansP , VanLeeuwenFE . Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes and Control2000;11(4):319‐44. [PUBMED: 10843444] ">Klip 2000</a>). </p> </li> </ul> </p> <p>Moreover, exposure to ovulation‐inducing agents has been implicated in the development of hyperplasia (excessive growth) of the endometrium ‐ a precursor of endometrial cancer (<a href="./references#CD010931-bbs2-0053" title="MiannayE , BoutemyJJ , Leroy‐BilliardM , GasnaultJP , LeroyJL . The possible endometrial risk of ovarian stimulation. A propos of 3 cases [Du risque endometrial de la stimulation ovarienne. A propos de trois cas]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1994;23(1):35‐8. [PUBMED: 8157888] ">Miannay 1994</a>). </p> </section> <section id="CD010931-sec-0034"> <h3 class="title" id="CD010931-sec-0034">Why it is important to do this review</h3> <p>Exposure to fertility drugs has increased over time, and hence evaluating the long‐term effects of ovulation‐inducing drugs on the risk of endometrial cancer is a matter of great importance. </p> <p>Over past decades, numerous studies investigating the association between fertility drugs and endometrial cancer risk have yielded conflicting or inconclusive results (<a href="./references#CD010931-bbs2-0052" title="LiLL , ZhouJ , QianXJ , ChenYD . Meta‐analysis on the possible association between in vitro fertilization and cancer risk. International Journal of Gynecological Cancer2013;23(1):16‐24. [PUBMED: 23211423] ">Li 2013</a>). We have recently examined the association between controlled ovarian hyperstimulation in the context of IVF and endometrial, ovarian or cervical cancer (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>). In that review, we observed an association between IVF and increased risk of endometrial cancer comparing exposed women with the general population, but this association dissipated when the comparison was made versus non‐exposed subfertile women. Broadening the research question, we now aim to evaluate all ovary‐stimulation drugs, not just those used in the context of IVF treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010931-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010931-sec-0035"></div> <p>To evaluate the association between the use of ovary‐stimulating drugs for the treatment of subfertility and the risk of endometrial cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010931-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010931-sec-0036"></div> <section id="CD010931-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010931-sec-0038"> <h4 class="title">Types of studies</h4> <p>We considered prospective and retrospective cohort studies and case‐control studies in this area. Case series, case reports and <i>in vitro</i> and animal studies were excluded. </p> </section> <section id="CD010931-sec-0039"> <h4 class="title">Types of participants</h4> <p>Women 18 years of age or older, with existing endometrium/uterine body. Women with preexisting cancer diagnoses of any type were excluded, along with women who had undergone fertility preservation treatment after receiving a cancer diagnosis. </p> </section> <section id="CD010931-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Any of the following regimens, offered alone or in combination, was considered as the exposure: clomiphene citrate (CC), gonadotropins, hCG and GnRH agonists/antagonists. </p> <p>Outcomes in subfertile women treated with these agents were compared with those of subfertile women who received no intervention and with those of control groups of women who had no fertility problems. </p> </section> <section id="CD010931-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD010931-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>Incidence of endometrial (uterine) cancer, clinically or histologically confirmed, at any time following treatment for subfertility. </p> </section> <section id="CD010931-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p>Incidence of endometrial hyperplasia (complex, simple atypical, and complex atypical).</p> </section> </section> </section> <section id="CD010931-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010931-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched CENTRAL (Issue 7, 2016), MEDLINE via Ovid (1960 to July week 3 2016) and Embase via Ovid (1980 to week 31 2016). We searched the CENTRAL database for reasons of completeness because, although this review was based on non‐randomised studies (NRSs), CENTRAL contains controlled clinical trials (CCTs), interrupted time series and controlled before and after series, in addition to randomised controlled trials (RCTs). </p> <p>The search terms included a combination of thesaurus‐based and free‐text terms. CENTRAL, MEDLINE and Embase search strategies are presented in <a href="./appendices#CD010931-sec-0102">Appendix 1</a>, <a href="./appendices#CD010931-sec-0103">Appendix 2</a> and <a href="./appendices#CD010931-sec-0104">Appendix 3</a>, respectively. </p> <p>We imposed no restriction on language and publication status. We searched from 1960 onwards, as the interventions sought were not available before that date. </p> </section> <section id="CD010931-sec-0046"> <h4 class="title">Searching other resources</h4> <p>Reference lists of included studies and any relevant systematic reviews identified were also searched to identify eligible studies for inclusion. The review authors tried to identify the relevant grey literature by looking at the following: </p> <p> <ul id="CD010931-list-0003"> <li> <p>OpenGrey, a system for grey literature produced in Europe, such as research reports, doctoral dissertations and conference papers (<a href="http://www.opengrey.eu/" target="_blank">http://www.opengrey.eu/</a>); </p> </li> <li> <p>ProQuest dissertation and thesis databases (<a href="http://www.proquest.com/en-US/catalogs/databases/detail/pqdt.shtml" target="_blank">http://www.proquest.com/en‐US/catalogs/databases/detail/pqdt.shtml</a>); </p> </li> <li> <p>Published or ongoing trials in the trial registers for ongoing and registered trials: '<a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>', a service of the US National Institutes of Health (<a href="http://clinicaltrials.gov/ct2/home" target="_blank">http://clinicaltrials.gov/ct2/home</a>) and <a href="http://www.controlled-trials.com" target="_blank">http://www.controlled‐trials.com</a>, as well as the World Health Organization International Trials Registry Platform search portal (<a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">http://www.who.int/trialsearch/Default.aspx</a>), and Physicians Data Query (<a href="http://www.nci.nih.gov" target="_blank">http://www.nci.nih.gov</a>); </p> </li> <li> <p>Conference proceedings and abstracts through ZETOC (<a href="http://zetoc.mimas.ac.uk" target="_blank">http://zetoc.mimas.ac.uk</a>) and WorldCat Dissertations; </p> </li> <li> <p>Reports of conferences in the following: <i>Gynecologic Oncology</i> (Annual Meeting of the American Society of Gynecologic Oncologists), <i>International Journal of Gynecological Cancer</i> (Annual Meeting of the International Gynecologic Cancer Society), <i>British Journal of Cancer</i> (British Cancer Research Meeting, Annual Meeting of the European Society of Medical Oncology (ESMO) and Annual Meeting of the American Society of Clinical Oncology (ASCO); </p> </li> <li> <p>Personal communication with experts in the field who had been conducting/had led research in the field and on the specific hypothesis of this review. </p> </li> </ul> </p> </section> </section> <section id="CD010931-sec-0047"> <h3 class="title" id="CD010931-sec-0047">Data collection and analysis</h3> <section id="CD010931-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We downloaded the search results to a special processing platform developed by Prodromos Kanavidis, a full description of which can be found in our recent publication (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>). </p> <p>We removed duplicates and all review coauthors were involved in selecting studies for eligibility. Review coauthors working in pairs (AS &amp; HS, SG &amp; TT, TS &amp; TP) assessed the allocation of titles and abstracts, so that each allocation portion was independently assessed by two review coauthors. We were not blinded to authors’ names and institutions, journal of publication or study results while assessing studies for potential inclusion. </p> <p>We excluded studies that clearly did not meet the inclusion criteria. For potentially relevant studies, we obtained the full text article for further assessment. We sent letters to study authors to ask for clarification about potentially relevant studies. We resolved all disagreements by consensus. </p> </section> <section id="CD010931-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>The review authors extracted data using a predesigned Excel file before copying the data into New Reference (<a href="./references#CD010931-bbs2-0056" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">Review Manager 2011</a>) for analysis. We previously had piloted the data extraction form (<a href="./appendices#CD010931-sec-0105">Appendix 4</a>) before using it in our published report (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>), which, however, focused solely on IVF. We extracted the data independently while working in pairs. We resolved all disagreements by consensus. </p> <p>The data we extracted included study general information (title, author, year, journal, geographical setting, and clinical setting), study characteristics (study period, number of participants per exposed/unexposed or case/control group, design, follow‐up, ascertainment of exposure and outcome, and matching factors), participant characteristics (inclusion/exclusion criteria, age, race, gynaecological and reproductive history, definition and causes of subfertility, gravidity, parity, and histological subtype of cancer), interventions (type and agent of fertility treatment, dosage of treatment, number of treatment cycles, age at first use, years since first use, reference population for the comparison, and general population or subfertile women), and risk of bias assessment data (cf. below, relevant sections). </p> <p>In addition, we extracted the following results, when available:</p> <p> <ul id="CD010931-list-0004"> <li> <p>Maximally adjusted (adjusted for all covariates) odds ratio (OR) and associated 95% confidence interval (CI), as defined by the study authors. </p> </li> <li> <p>Maximally adjusted risk ratio (RR) and associated 95% CI, as defined by the study authors. </p> </li> <li> <p>Maximally adjusted hazard ratio (HR) and associated 95% CI, based on the number of events (cases) and with consideration of the time‐to‐event. </p> </li> <li> <p>Standardised incidence ratio (SIR) and associated 95% CI, estimated as the ratio of observed over expected number of cases for the exposed group of women. </p> </li> <li> <p>Incidence rate ratio (IRR) and associated 95% CI, estimated from the number of cases per person‐years for exposed and unexposed women. </p> </li> <li> <p>Associated raw data for recalculation (data checking) or de novo estimation of missing measures. </p> </li> </ul> </p> </section> <section id="CD010931-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>As detailed below, RCTs were not identified, therefore the risk of bias assessment used methodology for non‐randomised studies (NRSs). </p> <p>The risk of bias was assessed in accordance with relevant sections of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010931-bbs2-0044" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), as well as in keeping with the rationale adopted in the most recent Cochrane review examining the association between ovarian cancer and ovary‐stimulation drugs for subfertility (<a href="./references#CD010931-bbs2-0057" title="RizzutoI , Larsen‐DisneyP , SmithLA . Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008215.pub2] ">Rizzuto 2013</a>). As suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Section 13.5.2.3), items included in the Newcastle‐Ottawa scale (<a href="./references#CD010931-bbs2-0067" title="WellsGA , SheaB , O’ConnellD , PetersonJ , WelchV , LososM , et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta‐analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed on Jan 1, 2014). ">Wells 2011</a>) were customised for inclusion in the detailed item‐to‐item list below. </p> <p>The assessment of risk of bias encompassed the examination of selection bias (comparability of groups and confounding/adjustment), performance bias, detection bias, attrition bias, reporting bias, and other bias. The qualifications 'low risk', 'high risk' and 'unclear risk' were adopted for each 'risk of bias' domain, in accordance with the guidelines published by the Newcastle‐Ottawa scale (<a href="./references#CD010931-bbs2-0067" title="WellsGA , SheaB , O’ConnellD , PetersonJ , WelchV , LososM , et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta‐analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed on Jan 1, 2014). ">Wells 2011</a>). </p> <section id="CD010931-sec-0051"> <h5 class="title">Selection bias</h5> <p>The following features of the study design were assessed for selection bias.</p> <section id="CD010931-sec-0052"> <h6 class="title">Comparability of groups</h6> <p> <ul id="CD010931-list-0005"> <li> <p>Consecutive recruitment cases (case‐control studies).</p> </li> <li> <p>Population‐based controls derived from the same population as cases (case‐control studies). </p> </li> <li> <p>Non‐exposed women drawn from the same population as the exposed cohort (cohort studies).</p> </li> <li> <p>Comparability on cause of subfertility, diabetes mellitus, polycystic ovary syndrome (PCOS), obesity (all studies). </p> </li> </ul> </p> </section> <section id="CD010931-sec-0053"> <h6 class="title">Confounding/Adjustment</h6> <p>For all studies, the following factors were evaluated as potential confounders, given that they represent known risk factors for endometrial cancer (<a href="./references#CD010931-bbs2-0026" title="AdamiHO , HunterD , TrichopoulosD . Textbook of Cancer Epidemiology. New York: Oxford University Press, 2008. ">Adami 2008</a>). </p> <p> <ul id="CD010931-list-0006"> <li> <p>Age.</p> </li> <li> <p>Use of oral contraceptives.</p> </li> <li> <p>Use of hormone replacement treatment (HRT).</p> </li> <li> <p>Age at menarche.</p> </li> <li> <p>Age at menopause.</p> </li> <li> <p>Parity.</p> </li> <li> <p>Smoking.</p> </li> <li> <p>Alcohol intake.</p> </li> <li> <p>Body mass index (BMI).</p> </li> <li> <p>Diabetes mellitus.</p> </li> <li> <p>PCOS.</p> </li> </ul> </p> </section> </section> <section id="CD010931-sec-0054"> <h5 class="title">Performance bias</h5> <p>The following features of the study design were evaluated.</p> <p> <ul id="CD010931-list-0007"> <li> <p>Blinding of participants and personnel regarding the allocated interventions (all studies). </p> </li> <li> <p>Exposure to ovary‐stimulation drugs was ascertained by a secure source, i.e. medical records or structured interviews (all studies). </p> </li> <li> <p>In cases in which a structured interview was performed, interviewers assessing exposure to fertility treatment were blinded to the presence of endometrial cancer (all studies). </p> </li> <li> <p>The same method was used to ascertain exposure to fertility drugs for both cases and controls (case‐control studies). </p> </li> </ul> </p> </section> <section id="CD010931-sec-0055"> <h5 class="title">Detection bias</h5> <p>The following feature was assessed.</p> <p> <ul id="CD010931-list-0008"> <li> <p>Assessors of cancer status were blinded to exposure status (all studies).</p> </li> </ul> </p> </section> <section id="CD010931-sec-0056"> <h5 class="title">Attrition bias</h5> <p>With respect to attrition bias, the following feature was examined.</p> <p> <ul id="CD010931-list-0009"> <li> <p>At least 80% of women in all groups were included in the final analysis (all studies).</p> </li> </ul> </p> </section> <section id="CD010931-sec-0057"> <h5 class="title">Selective reporting (reporting bias)</h5> <p>This domain assessed the uniformity in the undertaken analyses in each study. When outcomes were reported in a prespecified way, this indicated low risk of bias. However, instances of nonreported subanalyses or models differentially implemented across various cancer types in the same study, signalled high risk of bias. </p> </section> <section id="CD010931-sec-0058"> <h5 class="title">Other bias</h5> <p> <ul id="CD010931-list-0010"> <li> <p>Length of follow‐up was at least 10 years for the exposed group (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>), as endometrial cancer reaches its peak incidence after the age of 55 years, whereas IVF exposure occurs mostly during the late reproductive years (cohort studies). </p> </li> <li> <p>Study design as a non‐RCT study.</p> </li> </ul> </p> </section> </section> <section id="CD010931-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>Both primary and secondary outcome measures were expressed as odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs), standardised incidence ratios (SIRs), or incidence rate ratios (IRRs). The 95% confidence interval (CI) for log(SIR) were reconstructed via the term ± 1.96/(square root (O), where 'O' represented the observed number of events (<a href="./references#CD010931-bbs2-0028" title="AlderN ,  FentyJ ,  WarrenF ,  SuttonAJ ,  RushtonL ,  JonesDR ,  etal . Meta‐analysis of mortality and cancer incidence among workers in the synthetic rubber‐producing industry. American Journal of Epidemiology2006;164(5):405‐20. ">Alder 2006</a>). We intended to transform ORs, RRs and HRs into a single metric to reduce heterogeneity and to provide more robust estimates and analyse SIRs and IRRs separately; however, since the absolute risk of endometrial cancer is low, the four measures of association (ORs, HRs, SIRs, and IRRs) were expected to yield similar estimates of RR (<a href="./references#CD010931-bbs2-0026" title="AdamiHO , HunterD , TrichopoulosD . Textbook of Cancer Epidemiology. New York: Oxford University Press, 2008. ">Adami 2008</a>; <a href="./references#CD010931-bbs2-0051" title="LarssonSC , MantzorosCS , WolkA . Diabetes mellitus and risk of breast cancer: a meta‐analysis. International Journal of Cancer2007;121(4):856–62. ">Larsson 2007</a>), therefore no transformation was performed. </p> </section> <section id="CD010931-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was always the participant.</p> </section> <section id="CD010931-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>The corresponding authors of 'potentially relevant' and eligible studies were contacted by email when the need arose to obtain missing data, to ask for additional information or to request methodological clarification. We did not impute missing outcome data for any of the outcomes. </p> </section> <section id="CD010931-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>It is generally expected that non‐randomised studies will be more heterogeneous than randomised studies (<i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Section 13.6.1 (<a href="./references#CD010931-bbs2-0044" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), hence heterogeneity tolerance levels were adjusted accordingly. Inconsistency among studies was quantified by estimating I<sup>2</sup> (<a href="./references#CD010931-bbs2-0044" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). When considerable heterogeneity was noted (I<sup>2</sup> &gt; 80%), the pooled estimates were suppressed in the forest plot, and results were reported as narrative text or in descriptive tables. For levels of I<sup>2</sup> between 50% and 80%, heterogeneity was considered as moderate, and pooled analysis was attempted by using a RE model to allow for heterogeneity. Heterogeneity was also explored by means of a priori agreed subgroup analyses, by type of effect estimate. </p> </section> <section id="CD010931-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>As we included more than 10 studies in the review, we assessed publication bias using Egger’s formal statistical test ((<a href="./references#CD010931-bbs2-0040" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>); <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Section 10.4.3.1, (<a href="./references#CD010931-bbs2-0044" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) at the 90% level, and a funnel plot was constructed. We intended to also use an Egger's modified test (Harbord's test) to assess possible small‐study effect biases (<a href="./references#CD010931-bbs2-0043" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. ">Harbord 2006</a>), however the low number of included studies precluded this opportunity. </p> </section> <section id="CD010931-sec-0064"> <h4 class="title">Data synthesis</h4> <p>Our intention was to carry out meta‐analyses separately for RCTs in accordance with the intention‐to‐treat principle and for any non‐randomised studies (cohort and case‐control studies); however, no RCTs were identified for inclusion. </p> <p>We used RE models to present an analysis, where at least two relevant studies had to exist (<a href="./references#CD010931-bbs2-0035" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We also calculated separate pooled effect estimates for each risk ratio (RR) measures (and OR, HR, SIR, IRR). As mentioned before, the four relative measures were expected to yield similar estimates . As we described earlier, when possible, subgroup analyses by type of effect estimate were performed. </p> <p>Our intention was to perform sensitivity analyses by type of measure, yet this was not feasible due to the small number of included studies. Separate analyses were carried out for the different reference populations available (general population of women and subfertile women who did not receive fertility treatment). </p> <section id="CD010931-sec-0065"> <h5 class="title">'Summary of findings' tables</h5> <p>The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) Working Group system was used to build 'Summary of findings' tables as suggested by the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD010931-bbs2-0059" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schunemann 2011</a>). This included comparisons of risk of endometrial cancer in women exposed to any ovary‐stimulating drug (clomiphene citrate, gonadotropins, combination of clomiphene citrate and gonadotropins, and GnRH analogues) versus untreated subfertile women or women of the general population. </p> <p>The quality of evidence was very low for all comparisons. The observational nature of the included studies resulted in an initial rating of 'low' quality of evidence, which was further downgraded mostly because of the high risk of bias, and, in some comparisons, because of imprecision or inconsistency or both. </p> </section> </section> <section id="CD010931-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>According to data availability, the various therapeutic agents were evaluated by drug subtype (SERMs, gonadotropins, GnRH agonists and antagonists, hCG) and as individual drugs. Subgroup analyses were also performed for each ovary‐stimulation agent by type of effect measures. Separate analyses were performed by: </p> <p> <ul id="CD010931-list-0011"> <li> <p>gravidity and/or parity;</p> </li> <li> <p>age groups;</p> </li> <li> <p>causes of subfertility;</p> </li> <li> <p>histological type of cancer;</p> </li> <li> <p>dosage (low: 1000 mg or less; medium: 1000 to 2000 mg; high: 2000 mg or more of clomiphene citrate) </p> </li> <li> <p>number of cycles (low: 1 to 3; medium: 4 to 6; high: 7 or more);</p> </li> <li> <p>number of oocytes (0 to 3; 3 to 6; 6 to 10; 10 or more oocytes)</p> </li> <li> <p>studies including or excluding events during the first year of follow‐up (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>). </p> </li> </ul> </p> <p>Although we intended to perform meta‐regression analyses to adjust for mutual confounding, the small number of studies precluded any meaningful analysis. </p> <p>We did not need to statistically adjust for multiple analyses, as such adjustments pertain to multiple comparisons, which were not relevant in the context of our study (<a href="./references#CD010931-bbs2-0061" title="SergentanisTN , DiamantarasAA , PerlepeC , KanavidisP , SkalkidouA , PetridouET . IVF and breast cancer: a systematic review and meta‐analysis. Human Reproduction Update2014;20(1):106‐23. ">Sergentanis 2014</a>; <a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>). </p> </section> <section id="CD010931-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>As mentioned earlier, sensitivity analysis for each type of effect measure was not employed, as there were insufficient numbers of available studies. Similarly, sensitivity analyses based on the risk of bias assessment, although planned, were not carried out because of the high risk of bias in all of the examined studies. Sensitivity analyses were only performed for studies with mean or median follow‐up 10 years or more in the exposed cohort. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010931-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010931-sec-0068"></div> <section id="CD010931-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD010931-sec-0070"> <h4 class="title">Results of the search</h4> <p>Searching of all databases resulted in 8314 records: 3716 were retrieved from Medline; 4090 from Embase; and 508 from CENTRAL. Handsearch of references of relevant articles yielded 11 additional relevant studies. No relevant articles were identified by search of the grey literature. Removal of 1336 duplicates yielded 6978 unique records. After reading titles and abstracts, 40 articles were deemed potentially eligible, for which full text was obtained for further scrutiny. Of these, six studies were excluded (<a href="./references#CD010931-sec-0114" title="">Characteristics of excluded studies</a>). Thirty‐four articles corresponding to 19 studies were included. There were no studies meeting eligibility criteria that required translation. All the articles had an abstract in the English language. The selection of study process is graphically represented in a PRISMA Flow Diagram (<a href="#CD010931-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010931-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA Flow Diagram" data-id="CD010931-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA Flow Diagram</p> </div> </div> </div> </section> <section id="CD010931-sec-0071"> <h4 class="title">Included studies</h4> <p>Nineteen studies (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>) were included; <a href="./references#CD010931-sec-0113" title="">Characteristics of included studies</a> are presented in the respective section of the review. </p> <p>One study was conducted in Australia (<a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>), one in Denmark (<a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>), one in Finland (<a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>), two in Italy (<a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>), one in Netherlands (<a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>), one in Norway (<a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>), one in Sweden (<a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>), two in the UK (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>), seven in Israel (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; ; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>), and two in USA (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>). Thirteen studies were multi‐centre (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>), whereas six were single‐centre (<a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>). </p> <p>Sixteen of the studies were of retrospective cohort design (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>). Of these, eight studies identified women from IVF centres or reproductive endocrinology practices (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>), and five from registries (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>). One study identified its population from major obstetric units in West Jerusalem (<a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>) and another from the reimbursements for drugs or drug combinations that are specific to these subfertility treatments (<a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>). Lastly, one study recruited consecutive women who delivered at the sole hospital in Negev, Israel, serving the entire population (<a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>). Comparison of the risk of endometrial cancer in subfertile women receiving οvarian‐stimulating drugs treatment to that of untreated subfertile women, general population, or both was made by three (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>), eight (<a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>), and five studies (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>), respectively. Duration of follow‐up was more than 10 years for 10 studies (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>) and less than 10 years in six studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>). All studies were conducted between 1949 and 2011. </p> <p>Three studies were of case‐control design (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>), two of which included controls retrieved from the same hospitals as cases (<a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>), and one compared cases derived from a nationwide cancer registry with population‐based controls (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>). All studies were conducted between 1965 and 2006. </p> <p>Studies used clomiphene citrate, gonadotropins (human menopausal gonadotrophin (hMG) or human chorionic gonadotropin (hCG), and gonadotropin‐releasing hormone (GnRH) agonists, alone or in combination, as ovarian‐stimulating drugs, except for seven studies that did not provide data on the specific medications used (<a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>). Twelve studies reported neither the drug doses nor the number of cycles used for subfertility treatment (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>), while three studies only provided data on the number of fertility treatment cycles, but not the medicine dosages used (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>). </p> <p>No relevant studies of tamoxifen as an ovary‐stimulating drug for subfertility were identified. No studies were retrieved evaluating the association between ovarian‐stimulating drugs and endometrial hyperplasia. </p> </section> <section id="CD010931-sec-0072"> <h4 class="title">Excluded studies</h4> <p>Excluded studies, along with the reason for their exclusion, are presented in the <a href="./references#CD010931-sec-0114" title="">Characteristics of excluded studies</a> section. One study was excluded because data on endometrial cancer were not stated (<a href="./references#CD010931-bbs2-0023" title="KlemettiR , SevonT , GisslerM , HemminkiE . Complications of IVF and ovulation induction. Human Reproduction2005;20(12):3293‐300. [PUBMED: 16126753] ">Klemetti 2005</a>); notification failure email was received after sending an email requesting data to three authors of this study, including the corresponding author. Similarly, three studies were excluded, as they did not include data on exposure to ovarian stimulation drugs (<a href="./references#CD010931-bbs2-0020" title="BrintonLA , MeltonLJ3rd , MalkasianGDJr , BondA , HooverR . Cancer risk after evaluation for infertility. American Journal of Epidemiology1989;129(4):712‐22. [PUBMED: 2923119] ">Brinton 1989</a>; ; <a href="./references#CD010931-bbs2-0021" title="DeMicheleA , TroxelAB , BerlinJA , WeberAL , BuninGR , TurzoE , et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population‐based case‐control study. Journal of Clinical Oncology2008;26(25):4151‐9. [PUBMED: 18757329] ">DeMichele 2008</a>; <a href="./references#CD010931-bbs2-0025" title="YangHP , CookLS , WeiderpassE , AdamiHO , AndersonKE , CaiH , et al. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal of Cancer2015;112:925‐33. [PUBMED: 25688738] ">Yang 2015</a>). Specifically, no response was received to our email addressed to the authors of the study by DeMichele et al. (<a href="./references#CD010931-bbs2-0021" title="DeMicheleA , TroxelAB , BerlinJA , WeberAL , BuninGR , TurzoE , et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population‐based case‐control study. Journal of Clinical Oncology2008;26(25):4151‐9. [PUBMED: 18757329] ">DeMichele 2008</a>); no data were made available for the studies by Brinton et al (<a href="./references#CD010931-bbs2-0020" title="BrintonLA , MeltonLJ3rd , MalkasianGDJr , BondA , HooverR . Cancer risk after evaluation for infertility. American Journal of Epidemiology1989;129(4):712‐22. [PUBMED: 2923119] ">Brinton 1989</a>).), following our detailed communication with Dr. Louise Brinton. Regarding the eligibility of the pooled study by Yang et al. (<a href="./references#CD010931-bbs2-0025" title="YangHP , CookLS , WeiderpassE , AdamiHO , AndersonKE , CaiH , et al. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). British Journal of Cancer2015;112:925‐33. [PUBMED: 25688738] ">Yang 2015</a>), the authors were contacted in order to provide the results of the analyses pertaining to subfertility treatments. However, the authors did not provide any additional information, due to the considerably limited number of cases with subfertility treatment information. In one study (<a href="./references#CD010931-bbs2-0022" title="Holody‐ZarebaJ , KinalskiP , KinalskiM . Rating the risk factors for endometrial cancer in women. Ginekologia i Poloznictwo2014;31(1):54‐65. ">Holody‐Zareba 2014</a>) tamoxifen was used exclusively for breast cancer treatment. Lastly, in one study, clomiphene citrate was used specifically for treatment of polycystic ovary syndrome (<a href="./references#CD010931-bbs2-0024" title="WildS , PierpointT , JacobsH , McKeigueP . Long‐term consequences of polycystic ovary syndrome: results of a 31 year follow‐up study. Human Fertility2000;3(2):101‐5. [PUBMED: 11844363] ">Wild 2000</a>). </p> </section> </section> <section id="CD010931-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias of included studies is presented in the <a href="./references#CD010931-sec-0113" title="">Characteristics of included studies</a> section. <a href="#CD010931-fig-0002">Figure 2</a> depicts the assessment of the bias domains of each included study, while <a href="#CD010931-fig-0003">Figure 3</a> provides a graphical representation. No studies were found to be of low risk for bias, primarily because none of the studies was an RCT. </p> <div class="figure" id="CD010931-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010931-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010931-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010931-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010931-sec-0074"> <h4 class="title">Allocation</h4> <p>In all cohort studies, non‐exposed women were drawn from the same population as the exposed cohort; furthermore, all cohort studies, but six (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>), guaranteed that no women had a history of endometrial cancer at the beginning of follow‐up. However, none of the studies guaranteed the comparability of intervention and control group in terms of PCOS, diabetes mellitus, obesity and cause of subfertility, rendering them all at high risk of selection bias </p> <p>Population controls matched for age and geographical region were selected in one study (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>), whereas in the remaining two case‐control studies (<a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>), controls constituted women hospitalised for non‐neoplastic ailments. Nevertheless, in all case‐control studies, cases were histologically confirmed and consecutively recruited from a secure source. Similarly to the cohort studies, no comparability among the cases and controls on PCOS, diabetes mellitus, obesity and cause of infertility was ensured, </p> <p>Regarding adjustment for confounding factors among cohort studies, in one study (<a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>), only incidence rate ratios (IRRs) were calculated based on crude estimates and, in another one (<a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>), relative risks (RRs) were calculated on the basis of crude numbers. Six studies (<a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>: <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>) reported Standardized Incidence Ratios (SIRs) inherently adjusted just for age and calendar time. Apart from age, two studies adjusted for body mass Index (BMI) (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>) and one for smoking (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>). Regarding parity, two studies adjusted for parity at exit (after last ovulation‐induction cycle) (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>), whereas two studies (<a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>) controlled both for parity at the beginning of follow‐up and additional births during the follow‐up period. On the other hand, one study (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>) adjusted for gravidity. Moreover, three studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>) adjusted for socioeconomic status, one study (<a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>) for marital status and another one (<a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>) for family size, ovulatory disorders and geographic origin. Finally, adjustment for year of first visit in the fertility clinic was performed in three studies (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>). </p> <p>With respect to case‐control studies, one study controlled only for age (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>) through the matching process, whereas both of the remaining studies (<a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>) adjusted also for parity, BMI, oral contraceptive use, hormone replacement treatment use, and education. The latter study (<a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>) additionally adjusted for age at menarche, menopausal status, study centre, and calendar period of interview. </p> <p>None of the included studies provided appropriate adjustment for age at menopause, alcohol intake and diabetes mellitus, rendering them all at a high risk of bias. </p> </section> <section id="CD010931-sec-0075"> <h4 class="title">Blinding</h4> <p>None of the studies was blinded regarding the administration of allocated interventions; therefore, all studies were rated as high risk for performance bias. In fifteen of the cohort studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>: <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>), exposure to ovary‐stimulation drugs was ascertained by a secure source, namely, medical records, whereas in one study (<a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>), exposure was ascertained by an interview using a structured questionnaire, yet interviewers were not blinded to presence of endometrial cancer. Similarly, information on exposure in all case‐control studies was collected by trained interviewers using structured questionnaires, without being blinded to case‐control status. </p> <p>Regarding ascertainment of outcome, it was performed by record linkage in all cohort studies but one (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>). In one study (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>), information on the outcome of approximately12% of participants was based on questionnaires and no blinding process was reported. Regarding case‐control studies (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>), identification of endometrial cancer cases was also registry‐based. </p> </section> <section id="CD010931-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>The majority of cohort studies reported a completeness of follow‐up of at least 80%, which was considered adequate a priori, therefore, these studies were considered at low risk for attrition bias. In one study (<a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>), outcome data were derived from a local hospital and not from a registry, therefore implying attrition bias. In one study (<a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>), despite accounting completeness of follow‐up among its strengths, no quantification of completeness was provided, therefore the risk of attrition bias was considered unclear. Among case‐control studies, the proportion of nonparticipants was considerably low (&lt; 5%) in two studies (<a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>), whereas in one study (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>) this proportion reached 60%, so this study was judged as being at high risk for attrition bias. </p> </section> <section id="CD010931-sec-0077"> <h4 class="title">Selective reporting</h4> <p>Two studies (<a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>) were considered at high risk for selective reporting bias, as the first one (<a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>) did not report results by cause of subfertility, number of IVF cycles, and treatment outcome, while the latter (<a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>) provided results by cause of subfertility only for breast cancer. In another study (<a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>), it was unclear whether analyses by specific ovulation induction drug could be performed. Furthermore, in four studies (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>), selective reporting of results of statistical models was observed. Specifically, one study (<a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>) reported selectively the results of the multivariate regression models, another one (<a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>) did not provide the endometrial cancer‐specific Standarized Incidence Ratios and Poisson regression results. Likewise, one study (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>) did not present Cox regression models results and one study (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>) did not report on multivariate logistic regression models' results for the use of subfertility drugs or clomiphene citrate. Finally, one study (<a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>) did not provide results of stratified analyses for endometrial cancer. </p> </section> <section id="CD010931-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>Only 10 out of the 16 included cohort studies had an adequate length of follow‐up (&gt; 10 years) (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>: <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>). </p> </section> </section> <section id="CD010931-sec-0079"> <h3 class="title" id="CD010931-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD010931-tbl-0001"><b>Summary of findings for the main comparison</b> Exposure to any ovary‐stimulating drugs for subfertility compared to untreated subfertile women and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0002"><b>Summary of findings 2</b> Exposure to any ovary‐stimulating drugs for subfertility compared to general population and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0003"><b>Summary of findings 3</b> Exposure to clomiphene citrate for subfertility compared to untreated subfertile women and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0004"><b>Summary of findings 4</b> Exposure to clomiphene citrate for subfertility compared to general population and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0005"><b>Summary of findings 5</b> Exposure to gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0006"><b>Summary of findings 6</b> Exposure to gonadotropins for subfertility compared to general population and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0007"><b>Summary of findings 7</b> Exposure to clomiphene citrate and gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0008"><b>Summary of findings 8</b> Exposure to clomiphene citrate and gonadotropins for subfertility compared to general population and endometrial cancer risk</a>; <a href="./full#CD010931-tbl-0009"><b>Summary of findings 9</b> Exposure to GnRH analogues for subfertility compared to untreated subfertile women and endometrial cancer risk</a> </p> <section id="CD010931-sec-0080"> <h4 class="title">Any subfertility drug</h4> <section id="CD010931-sec-0081"> <h5 class="title">Any drug: studies versus unexposed subfertile women</h5> <p>Meta‐analysis of six studies, which included 156,774 participants with unexposed subfertile women as the control group (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>) indicated that exposure to any subfertility drug was not associated with the risk of endometrial cancer (pooled RR 0.96, 95% CI 0.67 to 1.37, I<sup>2</sup> = 0%; 6 studies,156,774 participants; quality of evidence: very low, <a href="./references#CD010931-fig-0007" title="">Analysis 1.1</a>, <a href="#CD010931-fig-0004">Figure 4</a>, <a href="./full#CD010931-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD010931-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Exposure to any drug; comparison group: subfertile; any, outcome: 2.1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Exposure to any drug; comparison group: subfertile; any, outcome: 2.1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> </div> <p>Analyses by parity (pooled RR 1.00, 95% CI 0.05 to 18.85, I<sup>2</sup> = 64% for parous (<a href="./references#CD010931-fig-0008" title="">Analysis 2.1</a>) and pooled RR 0.76, 95% CI 0.35 to 1.67, I<sup>2</sup> = 0% for nulliparous women (<a href="./references#CD010931-fig-0009" title="">Analysis 3.1</a>), and number of cycles (pooled RR 0.82, 95% CI 0.11 to 6.17, I<sup>2</sup> = 71% for low numbers (<a href="./references#CD010931-fig-0010" title="">Analysis 4.1</a>) and pooled RR 0.86, 95% CI: 0.46 to 1.59, I<sup>2</sup> = 0% for medium numbers (<a href="./references#CD010931-fig-0011" title="">Analysis 5.1</a>) in two studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>) confirmed the null pattern. </p> </section> <section id="CD010931-sec-0082"> <h5 class="title">Any drug: studies versus the general population</h5> <p>Conversely, meta‐analysis of 15 studies, including 1,762,829 participants, (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>; <a href="./references#CD010931-bbs2-0014" title="ParazziniF , RicciE , RosaC , NegriE , LaVecchiaC . Risk of endometrial cancer after use of fertility drugs. Human Reproduction2001; Vol. 16, issue 1:196. [PUBMED: 11139563] ">Parazzini 2001</a>; <a href="./references#CD010931-bbs2-0015" title="ParazziniF , PelucchiC , TalaminiR , MontellaM , LaVecchiaC . Use of fertility drugs and risk of endometrial cancer in an Italian case‐control study. European Journal of Cancer Prevention2010;19(6):428‐30. [PUBMED: 20634699] ZucchettoA , SerrainoD , PoleselJ , NegriE , DePaoliA , Dal MasoL , et al. Hormone‐related factors and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer Prevention2009;18(4):316‐21. [PUBMED: 19554665] ">Parazzini 2010</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>) adopting the general population as reference, suggested an increased risk of endometrial cancer associated with exposure to any subfertility drug (pooled RR 1.75, 95% CI 1.18 to 2.61, I<sup>2</sup> = 65%; 15 studies, 1,762,829 participants; quality of evidence: very low, <a href="./references#CD010931-fig-0012" title="">Analysis 6.1</a>, <a href="#CD010931-fig-0005">Figure 5</a>, <a href="./full#CD010931-tbl-0002">summary of findings Table 2</a>). </p> <div class="figure" id="CD010931-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> </div> <p>Analyses by number of cycles, (pooled RR 2.33, 95% CI 0.93 to 5.87, 2 studies, I<sup>2</sup> = 21% for low numbers (<a href="./references#CD010931-fig-0013" title="">Analysis 7.1</a>); pooled RR 3.39, 95% CI 0.77 to 14.87, 2 studies, I<sup>2</sup> = 46% for medium numbers (<a href="./references#CD010931-fig-0014" title="">Analysis 8.1</a>), including two studies (<a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>), did not demonstrate a significant effect with a high level of inconsistency. Analyses by number of oocytes (two studies, <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>) found an association with risk of endometrial cancer for ten or more retrieved oocytes (0 to 3 oocytes retrieved: pooled RR 2.95, 95% CI 0.47 to 18.57, 2 studies, I<sup>2</sup> = 58% (<a href="./references#CD010931-fig-0015" title="">Analysis 9.1</a>); more than 10 oocytes retrieved: pooled RR 6.93, 95% CI 2.24 to 21.50, 2 studies, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0016" title="">Analysis 10.1</a>). </p> </section> </section> <section id="CD010931-sec-0083"> <h4 class="title">Clomiphene citrate</h4> <section id="CD010931-sec-0084"> <h5 class="title">Clomiphene citrate: studies versus unexposed subfertile women</h5> <p>Using unexposed subfertile women as controls, five studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>), reported on the association between exposure to clomiphene citrate and risk of endometrial cancer; meta‐analysis indicated an increased risk (pooled RR 1.32, 95% CI 1.01 to 1.71,I<sup>2</sup> = 0%; 5 studies, 92,849 participants; quality of evidence: very low (<a href="./references#CD010931-fig-0017" title="">Analysis 11.1</a>, <a href="./full#CD010931-tbl-0003">summary of findings Table 3</a>). </p> <p>Analyses by dosage pointed to an association only at high dosage (pooled RR 1.69, 95% CI 1.07 to 2.68, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0020" title="">Analysis 14.1</a>), whereas the analyses pertaining to low dosage (pooled RR 1.30, 95% CI 0.78 to 2.17, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0018" title="">Analysis 12.1</a>) and medium dosage (pooled RR 1.27, 95% CI 0.76 to 2.13, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0019" title="">Analysis 13.1</a>), including two studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>) did not yield an association. </p> <p>The analysis by number of cycles (three studies, <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>) was in accordance with that pertaining to dosage, as the effect was evident in women receiving a high number of cycles (pooled RR 1.69, 95% CI 1.16 to 2.47, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0022" title="">Analysis 16.1</a>) but not in those exposed to a medium number of cycles (pooled RR 1.22, 95% CI 0.87 to 1.73, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0021" title="">Analysis 15.1</a>). </p> <p>Analyses by parity in two studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>) did not yield any associations (pooled RR 1.68, 95% CI 0.82 to 3.43, I<sup>2</sup> = 0% for parous women (<a href="./references#CD010931-fig-0023" title="">Analysis 17.1</a>); pooled RR 1.01, 95% CI 0.51 to 2.01, I<sup>2</sup> = 29% for nulliparous women (<a href="./references#CD010931-fig-0024" title="">Analysis 18.1</a>). </p> </section> <section id="CD010931-sec-0085"> <h5 class="title">Clomiphene citrate: studies versus the general population</h5> <p>Four studies, encompassing 19,614 participants (<a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>), reported on exposure to clomiphene citrate compared to a general population reference group; the meta‐analysis yielded a pooled RR 1.87 and 95% CI 1.00 to 3.48, I<sup>2</sup> = 46%; 4 studies, 19,614 participants; with high risk of bias and very low quality of evidence (<a href="./references#CD010931-fig-0025" title="">Analysis 19.1</a>, <a href="./full#CD010931-tbl-0004">summary of findings Table 4</a>). </p> <p>Analyses by dosage, including two studies (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>), suggested an association at high dosage (pooled RR 5.48, 95% CI 2.28 to 13.17, I<sup>2</sup> = 17% (<a href="./references#CD010931-fig-0027" title="">Analysis 21.1</a>), whereas the analysis pertaining to low dosage (pooled RR 1.52, 95% CI 0.48 to 4.78, I<sup>2</sup> = 2% (<a href="./references#CD010931-fig-0026" title="">Analysis 20.1</a>) did not yield any association. </p> <p>Analysis by number of cycles, based on two studies (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>), found that there may be an effect in women receiving a high number of cycles (7 or more) (pooled RR 4.17, 95% CI 1.35 to 12.94, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0029" title="">Analysis 23.1</a>) but there was no difference in women who had received three cycles or fewer (pooled RR 1.82, 95% CI 0.56 to 5.90, I<sup>2</sup> = 6% (<a href="./references#CD010931-fig-0028" title="">Analysis 22.1</a>). . </p> </section> </section> <section id="CD010931-sec-0086"> <h4 class="title">Gonadotropins</h4> <p>Analysis of four studies, with unexposed subfertile women as the control group (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>), found that exposure to gonadotropins may be associated with increased risk of endometrial cancer (pooled RR 1.55, 95% CI 1.03 to 2.34, I<sup>2</sup> = 0%; 4 studies, 17,769 participants; quality of evidence: very low (<a href="./references#CD010931-fig-0030" title="">Analysis 24.1</a>, <a href="./full#CD010931-tbl-0005">summary of findings Table 5</a>). This finding was mainly associated with one study (<a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>). Analysis of the two studies (1595 participants) assessing risk against the general population (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>) demonstrated no difference (pooled RR 2.12, 95% CI 0.79 to 5.64, I<sup>2</sup> = 0%; 2 studies, 1595 participants; quality of evidence: very low (<a href="./references#CD010931-fig-0033" title="">Analysis 27.1</a>, <a href="./full#CD010931-tbl-0006">summary of findings Table 6</a>).No consistent dose‐response pattern arose from the subanalyses by number of cycles with subfertile women as the control group (two studies, <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>); medium number of cycles (pooled RR 1.61, 95% CI 1.00 to 2.60, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0031" title="">Analysis 25.1</a>); high number of cycles (pooled RR 1.90, 95% CI 0.80 to 4.52, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0032" title="">Analysis 26.1</a>). </p> </section> <section id="CD010931-sec-0087"> <h4 class="title">Combination of clomiphene citrate and gonadotropins</h4> <p>The analysis of two studies (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>) with unexposed subfertile women as controls (6,345 participants) indicated no association between the combination of clomiphene citrate with gonadotropins on the risk of endometrial cancer (pooled RR 1.18, 95% CI 0.57 to 2.44, I<sup>2</sup> = 0%; 2 studies, 6345; quality of evidence: very low (<a href="./references#CD010931-fig-0034" title="">Analysis 28.1</a>, <a href="./full#CD010931-tbl-0007">summary of findings Table 7</a>). The respective analysis of three studies (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>) versus the general population (3 studies, 7,789 participants) suggested there was a positive association (pooled RR 2.99, 95% CI 1.53 to 5.86, I<sup>2</sup> = 44%, quality of evidence: very low (<a href="./references#CD010931-fig-0035" title="">Analysis 29.1</a>, <a href="./full#CD010931-tbl-0008">summary of findings Table 8</a>). </p> </section> <section id="CD010931-sec-0088"> <h4 class="title">GnRH</h4> <p>Meta‐analysis of two studies, with 42,558 participants (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>), reporting on the risk of endometrial cancer after exposure to GnRH (vs subfertile women) found no difference in the risk of endometrial cancer, either at the overall analysis (pooled RR 1.21, 95% CI: 0.65 to 2.27, I<sup>2</sup> = 0%, 2 studies, 42,558 participants; quality of evidence: very low (<a href="./references#CD010931-fig-0036" title="">Analysis 30.1</a>, <a href="./full#CD010931-tbl-0009">summary of findings Table 9</a>) or at the analyses (two studies, <a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>) by parity (pooled RR 2.88, 95% CI 0.95 to 8.71, I<sup>2</sup> = 0% for parous women (<a href="./references#CD010931-fig-0037" title="">Analysis 31.1</a>) and pooled RR 0.75, 95% CI 0.34 to 1.63, I<sup>2</sup> = 0% for nulliparous women (<a href="./references#CD010931-fig-0038" title="">Analysis 32.1</a>). </p> </section> <section id="CD010931-sec-0089"> <h4 class="title">Sensitivity analyses</h4> <p>Where possible, sensitivity analyses were conducted excluding studies with inadequate follow‐up periods in the exposed cohort (mean or median &lt; 10 years). In the analysis of any subfertility drug among the subfertile population, the results remained unchanged after exclusion of studies with inadequate follow‐up (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>) (pooled RR 0.95, 95% CI 0.63 to 1.44, 2 studies, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0039" title="">Analysis 33.1</a>). Similarly, the robustness of the findings for the general population was replicated in sensitivity analysis of the five studies (<a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a> ;<a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>) with long enough follow‐up (pooled RR 2.52, 95% CI 1.80 to 3.53, I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0040" title="">Analysis 34.1</a>). Consistent with the respective overall analyses were also the findings for subfertile women in the sensitivity analyses for exposure to clomiphene (pooled RR 1.35, 95% CI 1.03 to 1.78, 4 studies (exclusion of <a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>), I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0041" title="">Analysis 35.1</a>) and gonadotropins (pooled RR 1.82, 95% CI 1.01 to 3.27, 3 studies (exclusion of <a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>), I<sup>2</sup> = 0% (<a href="./references#CD010931-fig-0043" title="">Analysis 37.1</a>), as well as for the analysis versus the general population regarding clomiphene (pooled RR 2.08, 95% CI 1.01 to 4.28, 3 studies (exclusion of <a href="./references#CD010931-bbs2-0001" title="BenshushanA , PaltielO , BrzezinskiA , TanosV , BarchanaM , ShoshaniO , et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology2001;98(1):53‐7. [PUBMED: 11516800] BenshushanA , PaltielO , RojanskyN , BrzezinskiA , LauferN . IUD use and the risk of endometrial cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology2002;105(2):166‐9. [PUBMED: 12381481] ">Benshushan 2001</a>), I<sup>2</sup> = 58% (<a href="./references#CD010931-fig-0042" title="">Analysis 36.1</a>) and the combination of clomiphene citrate and gonadotropins (pooled RR 3.58, 95% CI 1.82 to 7.06, 2 studies (exclusion of <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>), I<sup>2</sup> = 44% (<a href="./references#CD010931-fig-0044" title="">Analysis 38.1</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010931-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010931-sec-0090"></div> <section id="CD010931-sec-0091"> <h3 class="title" id="CD010931-sec-0091">Summary of main results</h3> <p>We examined the effect of ovarian‐stimulating drugs for subfertility on the risk of endometrial cancer. All included studies were non‐randomised: therefore, the quality of the evidence was very low and downgrading was apparent in the GRADE assessment. Similarly to the two previous meta‐analyses by our team (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>; <a href="./references#CD010931-bbs2-0061" title="SergentanisTN , DiamantarasAA , PerlepeC , KanavidisP , SkalkidouA , PetridouET . IVF and breast cancer: a systematic review and meta‐analysis. Human Reproduction Update2014;20(1):106‐23. ">Sergentanis 2014</a>), studies adopting the general population, in contrast to subfertile women, as the control group, yielded different results. Indeed, results of studies examining comparisons versus the general population were affected by the superimposed effect of subfertility (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>; <a href="./references#CD010931-bbs2-0061" title="SergentanisTN , DiamantarasAA , PerlepeC , KanavidisP , SkalkidouA , PetridouET . IVF and breast cancer: a systematic review and meta‐analysis. Human Reproduction Update2014;20(1):106‐23. ">Sergentanis 2014</a>), the latter representing a well established risk factor for endometrial cancer (<a href="./references#CD010931-bbs2-0032" title="CetinI , CozziV , AntonazzoP . Infertility as a cancer risk factor ‐ a review. Placenta2008;29 Suppl B:169‐77. ">Cetin 2008</a>). </p> <p>The quality of the evidence was very low due to serious risk of bias and indirectness by GRADE assessment. All studies were at high risk of bias due to the non‐randomised design and bias due to confounders was not taken into account in the studies. The clinical bias should also be emphasized, as the groups were often markedly different and had different underlying risks of endometrial cancer. </p> <p>The six studies with unexposed subfertile women used as the control group did not suggest an association between exposure to any drug and risk of endometrial cancer (RR 0.96, 95% CI 0.67 to 1.37, 156,774 participants; <a href="./references#CD010931-fig-0007" title="">Analysis 1.1</a>, <a href="#CD010931-fig-0004">Figure 4</a>). Drug‐specific analyses of the five available studies, found an association between exposure to clomiphene citrate and risk of endometrial cancer (RR 1.32, 95% CI 1.01 to 1.71, 92,849 participants; <a href="./references#CD010931-fig-0017" title="">Analysis 11.1</a>), especially at high doses (RR 1.69, 95% CI 1.07 to 2.68; <a href="./references#CD010931-fig-0020" title="">Analysis 14.1</a>) and high number of cycles (RR 1.69, 95% CI 1.16 to 2.47; <a href="./references#CD010931-fig-0022" title="">Analysis 16.1</a>), but it was not possible to separate the effect of clomiphene from the underlying condition leading to the need for multiple cycles or high doses from the evidence available. There was no consistent association between gonadotrophin exposure and risk of endometrial cancer, when unexposed subfertile women were used as the control group (RR 1.55, 95% CI 1.03 to 2.34, 4 studies, 17,769 participants; <a href="./references#CD010931-fig-0030" title="">Analysis 24.1</a>), nor was there a consistent dose‐response effect (<a href="./references#CD010931-fig-0031" title="">Analysis 25.1</a>; <a href="./references#CD010931-fig-0032" title="">Analysis 26.1</a>). </p> <p>Clomiphene citrate, one of the most widely used agents to treat subfertility, directly interacts with the oestrogen receptors in the endometrium (<a href="./references#CD010931-bbs2-0054" title="NakamuraY , OnoM , YoshidaY , SuginoN , UedaK , KatoH . Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertility and Sterility1997;67(2):256‐60. [PUBMED: 9022599] ">Nakamura 1997</a>; <a href="./references#CD010931-bbs2-0042" title="GoldsteinSR , SiddhantiS , CiacciaAV , PlouffeLJr . A pharmacological review of selective oestrogen receptor modulators. Human Reproduction Update2000;6(3):212‐24. ">Goldstein 2000</a>) as a selective oestrogen receptor modulator, with chemical properties similar to tamoxifen (<a href="./references#CD010931-bbs2-0063" title="SovinoH , Sir‐PetermannT , DevotoL . Clomiphene citrate and ovulation induction. Reproductive BioMedicine Online2002;4(3):303‐10. ">Sovino 2002</a>), which has been associated with an increased risk of endometrial cancer (<a href="./references#CD010931-bbs2-0046" title="HuR , Hilakivi‐ClarkeL , ClarkeR . Molecular mechanisms of tamoxifen‐associated endometrial cancer. Oncology Letters2015;9(4):1495‐1501. ">Hu 2015</a>). The dose‐response effects may suggest a causative effect (<a href="./references#CD010931-bbs2-0045" title="HillAB . The environment and disease: association or causation?. Proceedings of the Royal Society of Medicine1965;58:295‐300. ">Hill 1965</a>). However, high doses of clomiphene citrate are very likely to have been preferentially prescribed to women with PCOS, which is a known risk factor for endometrial cancer (<a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>). </p> <p>Studies comparing subfertile women treated with fertility drugs compared to a general population inherently introduced significant bias, especially since nulliparity is a known risk factor for endometrial cancer, whereas pregnancy has a protective effect. Meta‐analyses from these studies comparing exposure to any subfertility agent versus the general population demonstrated a 1.8‐fold increased risk of endometrial cancer (RR 1.75, 95% CI 1.18 to 2.61, 15 studies, 1,762,829 participants; <a href="./references#CD010931-fig-0012" title="">Analysis 6.1</a>). Higher numbers of retrieved oocytes (RR 6.93, 95% CI 2.24 to 21.50; <a href="./references#CD010931-fig-0016" title="">Analysis 10.1</a>) did appear to be associated with an increased risk of endometrial cancer, although the data were based on a highly selected, small number of women, as was the association between the high number of clomiphene cycles (RR 4.17, 95% CI 1.35 to 12.94; <a href="./references#CD010931-fig-0029" title="">Analysis 23.1</a>) or high doses of clomiphene (RR 5.48, 95% CI 2.28 to 13.17; <a href="./references#CD010931-fig-0027" title="">Analysis 21.1</a>). </p> </section> <section id="CD010931-sec-0092"> <h3 class="title" id="CD010931-sec-0092">Overall completeness and applicability of evidence</h3> <p>The included studies based their exposed groups on women who attended subfertility clinics at major hospitals. Most studies relied upon cancer registries for completeness of case ascertainment. The results may demonstrate a possible association between the requirement for treatment with some fertility medications, especially at high doses or high number of cycles, and an increased risk of endometrial cancer, compared to women who do not require treatment. However, the evidence cannot say whether this a causative effect or merely reflects an increased incidence of known risk factors for endometrial cancer in women who require fertility treatment (e.g. nulliparity, PCOS, obesity). </p> </section> <section id="CD010931-sec-0093"> <h3 class="title" id="CD010931-sec-0093">Quality of the evidence</h3> <p>Overall, the quality of the evidence was derived from non‐randomised studies and was rated as very low according to GRADE methodology (<a href="./full#CD010931-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010931-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010931-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD010931-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD010931-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD010931-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD010931-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD010931-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD010931-tbl-0009">summary of findings Table 9</a>), mostly on account of the studies being at very high risk of bias. Moderate inconsistency was highlighted in only two comparisons ( I² &gt; 40%, <a href="./references#CD010931-fig-0025" title="">Analysis 19.1</a>; <a href="./references#CD010931-fig-0035" title="">Analysis 29.1</a>). Furthermore, all comparisons suffered from serious indirectness, mostly on account of differences in the studied populations and the presence, as well as causes, of underlying subfertility. </p> <p>A variety of limitations in the individual studies may have further interfered with the quality of evidence. Specifically, the lack of adjustment for meaningful confounding factors, as well as the relatively short follow‐up periods of study subjects in relation to peak incidence of endometrial cancer, should be highlighted. . Only 10 (<a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>: <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>) out of the 16 included cohort studies (<a href="./references#CD010931-bbs2-0002" title="BrintonLA , TrabertB , ShalevV , LunenfeldE , SellaT , ChodickG . In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertility and Sterility2013;99(5):1189‐96. [PUBMED: 23375197] ">Brinton 2013a</a>; <a href="./references#CD010931-bbs2-0003" title="AlthuisMD , MoghissiKS , WesthoffCL , ScocciaB , LambEJ , LubinJH , et al. Uterine cancer after use of clomiphene citrate to induce ovulation. American Journal of Epidemiology2005;161(7):607‐15. [PUBMED: 5781949] AlthuisMD , ScocciaB , LambEJ , MoghissiKS , WesthoffCL , MabieJE , et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. American Journal of Obstetrics and Gynecology2005;193(3 Pt 1):668‐74. [PUBMED: 16150258] BrintonLA , WesthoffCL , ScocciaB , LambEJ , AlthuisMD , MabieJE , et al. Causes of infertility as predictors of subsequent cancer risk.. Epidemiology2005;16(4):500‐7. [PUBMED: 15951668] BrintonLA , WesthoffCL , ScocciaB , LambEJ , TrabertB , NiwaS , et al. Fertility drugs and endometrial cancer risk: results from an extended follow‐up of a large infertility cohort. Human Reproduction2013;28(10):2813‐21. [PUBMED: 23943795] ">Brinton 2013b</a>; <a href="./references#CD010931-bbs2-0004" title="Calderon‐MargalitR , FriedlanderY , YanetzR , KleinhausK , PerrinMC , ManorO , et al. Cancer risk after exposure to treatments for ovulation induction. American Journal of Epidemiology2009;169(3):365‐75. [PUBMED: 19037008] ">Calderon‐Margalit 2009</a>; <a href="./references#CD010931-bbs2-0005" title="DorJ , Lerner‐GevaL , RabinoviciJ , ChetritA , LevranD , LunenfeldB , et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertility and Sterility2002;77(2):324‐7. [PUBMED: 11821091] ">Dor 2002</a>; <a href="./references#CD010931-bbs2-0006" title="Silva IdosS , WarkPA , McCormackVA , MayerD , OvertonC , LittleV , et al. Ovulation‐stimulation drugs and cancer risks: a long‐term follow‐up of a British cohort. British Journal of Cancer2009;100(11):1824‐31. [PUBMED: 19436296] ">Dos Santos Silva 2009</a>; <a href="./references#CD010931-bbs2-0007" title="DoyleP , MaconochieN , BeralV , SwerdlowAJ , TanSL . Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction2002;17(8):2209‐13. [PUBMED: 12151460] ">Doyle 2002</a>; <a href="./references#CD010931-bbs2-0008" title="JensenA , SharifH , KjaerSK . Use of fertility drugs and risk of uterine cancer: results from a large Danish population‐based cohort study. American Journal of Epidemiology2009;170(11):1408‐14. [PUBMED: 19884127] JensenA , SharifH , OlsenJH , KjaerSK . Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American Journal of Epidemiology2008;168(1):49‐57. [PUBMED: 18448441] ">Jensen 2009</a>; <a href="./references#CD010931-bbs2-0009" title="KessousR , DavidsonE , MeirovitzM , SergienkoR , SheinerE . The risk of female malignancies after fertility treatments: a cohort study with 25‐year follow‐up. Journal of Cancer Research and Clinical Oncology2016;142(1):287‐93. ">Kessous 2016</a>: <a href="./references#CD010931-bbs2-0010" title="BurgerCW , KlipH , VanLeeuwenFE . Risk of hormone related cancers after ovarian stimulation for IVF in a cohort of 25,152 women. International Journal of Gynecological Cancer2004;14 Suppl 1:5. Van denBelt‐DuseboutAW , SpaanM , BurgerCW , VanLeeuwenFE . Risk of endometrial cancer after ovarian stimulation for in‐vitro fertilization. Fertility and Sterility2014;102:e51. ">Klip 2004</a>; <a href="./references#CD010931-bbs2-0011" title="KallenB . Maternal morbidity and mortality in in‐vitro fertilization. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology2008;22(3):549‐58. [PUBMED: 18400561] KallenB , FinnstromO , LindamA , NilssonE , NygrenKG , OlaussonPO . Malignancies among women who gave birth after in vitro fertilization.. Human Reproduction2011;26(1):253‐8. [PUBMED: 21088017] KristianssonP , BjorO , WramsbyH . Tumour incidence in Swedish women who gave birth following IVF treatment. Human Reproduction2007;22(2):421‐6. [PUBMED: 17071821] ">Kristiansson 2007</a>; <a href="./references#CD010931-bbs2-0012" title="Lerner‐GevaL , RabinoviciJ , OlmerL , BlumsteinT , MashiachS , LunenfeldB . Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow‐up. Gynecological Endocrinology2012;28(10):809‐14. [PUBMED: 22475084] ModanB , RonE , Lerner‐GevaL , BlumsteinT , MenczerJ , RabinoviciJ , et al. Cancer incidence in a cohort of infertile women.. American Journal of Epidemiology1998;147(11):1038‐42. [PUBMED: 9620047] RonE , LunenfeldB , MenczerJ , BlumsteinT , KatzL , OelsnerG , et al. Cancer incidence in a cohort of infertile women. American Journal of Epidemiology1987;125(5):780‐90. [PUBMED: 3565353] ">Lerner‐Geva 2012</a>; <a href="./references#CD010931-bbs2-0013" title="LukeB , BrownMB , SpectorLG , MissmerSA , LeachRE , WilliamsM , et al. Cancer in women after assisted reproductive technology. Fertility and Sterility2015;104(5):1218‐26. ">Luke 2015</a>: <a href="./references#CD010931-bbs2-0016" title="PotashnikG , Lerner‐GevaL , GenkinL , ChetritA , LunenfeldE , PorathA . Fertility drugs and the risk of breast and ovarian cancers: results of a long‐term follow‐up study. Fertility and Sterility1999;71(5):853‐9. [PUBMED: 10231045] ">Potashnik 1999</a>; <a href="./references#CD010931-bbs2-0017" title="ReigstadMM , LarsenIK , MyklebustTA , RobsahmTE , OldereidNB , OmlandAK , et al. Cancer risk among parous women following assisted reproductive technology. Human Reproduction2015;30:1952‐63. [PUBMED: 26113657] ReigstadMM , LarsenIK , RobsahmTE , OldereidNB , VangenS , StorengR . Cancer risk in parous women following fertility treatment: utilising the medical birth registry and the cancer registry of Norway. European Journal of Epidemiology2013;28:S12. ">Reigstad 2015</a>; <a href="./references#CD010931-bbs2-0018" title="VennA , HemminkiE , WatsonL , BruinsmaF , HealyD . Mortality in a cohort of IVF patients. Human Reproduction2001;16(12):2691‐6. [PUBMED: 11726597] VennA , JonesP , QuinnM , HealyD . Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecologic Oncology2001;82(1):64‐8. [PUBMED: 11426963] VennA , WatsonL , BruinsmaF , GilesG , HealyD . Risk of cancer after use of fertility drugs with in‐vitro fertilisation. Lancet1999;354(9190):1586‐90. [PUBMED: 10560672] VennA , WatsonL , LumleyJ , GilesG , KingC , HealyD . Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet1995;346(8981):995‐1000. [PUBMED: 7475593] ">Venn 1999</a>; <a href="./references#CD010931-bbs2-0019" title="Yli‐KuhaAN , GisslerM , KlemettiR , LuotoR , HemminkiE . Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Human Reproduction2012;27(4):1149‐55. [PUBMED: 22343550] ">Yli‐Kuha 2012</a>) encompassed a follow‐up period longer than 10 years among exposed women. Both PCOS and obesity, which predispose to development of endometrial cancer at a young age, are known causes of subfertility and therefore may have skewed the detection of young endometrial cancers in the cohorts, under‐reporting the overall risk of endometrial cancer in the control groups. However, these findings were replicated in sensitivity analyses, which excluded studies with short follow‐up. The fact that studies were registry‐based may have minimized attrition and detection bias. </p> </section> <section id="CD010931-sec-0094"> <h3 class="title" id="CD010931-sec-0094">Potential biases in the review process</h3> <p>This systematic review was limited to observational, non‐randomised studies. It was unable to demonstrate causation, merely association, although RCTs in this area are nearly impossible, since it would be ethically challenging to restrict fertility treatment to women requiring it. The meta‐analysis used a publication‐based approach and obtaining individual participant data for each study was not possible, which could have allowed adjustment for confounding factors across included studies. </p> <p>On the positive side, we adopted clear definitions of exposures and outcome and we adhered to procedures that minimized extraction, recording and retrieval bias, by carefully searching for 'grey' literature; furthermore, no language restriction was adopted. No evidence of publication bias was documented in the only analysis with more than ten study arms, namely that referring to any subfertility drug, with general population women as the reference group (<a href="./references#CD010931-fig-0012" title="">Analysis 6.1</a>), as shown in <a href="#CD010931-fig-0006">Figure 6</a> and verified by Egger's test (P = 0.102). </p> <div class="figure" id="CD010931-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> </div> <p>One other source of bias in the review was due to multiple analyses, without adjustment for multiple analyses (<a href="./references#CD010931-bbs2-0047" title="JakobsenJC , GluudC , WinkelP , LangeT , WetterslevJ . The thresholds for statistical and clinical significance ‐ a five‐step procedure for evaluation of intervention effects in randomised clinical trials.. BMC Medical Research Methodology2014;14:34. ">Jakobsen 2014a</a>, <a href="./references#CD010931-bbs2-0048" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods.. BMC Medical Research Methodology2014;14:120. ">Jakobsen 2014b</a>, <a href="./references#CD010931-bbs2-0049" title="JakobsenJC , WetterslevJ , LangeT , GluudC . Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews. Cochrane Database of Systematic Reviews2016; Vol. 3:DOI: 10.1002/14651858.ED000111. ">Jakobsen 2016</a>). </p> </section> <section id="CD010931-sec-0095"> <h3 class="title" id="CD010931-sec-0095">Agreements and disagreements with other studies or reviews</h3> <p>In general, there is a paucity of publications on the association of exposure to subfertility drugs and endometrial cancer. This meta‐analysis is in agreement with the previous systematic review by our team (<a href="./references#CD010931-bbs2-0062" title="Siristatidis C ,  Sergentanis TN ,  KanavidisP ,  TrivellaM ,  SotirakiM ,  MavromatisI ,  etal . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta‐analysis. Human Reproduction Update2013;19(2):105‐23. ">Siristatidis 2013</a>), which focused exclusively on the context of IVF . Specifically, in that study, risk of endometrial cancer was increased among women undergoing controlled ovarian hyperstimulation for IVF versus the general population (RR 2.04, 95% CI 1.22 to 3.43); on the other hand, no difference in risk was found versus untreated subfertile women (RR 0.45, 95% CI 0.18 to 1.14)<b>.</b> </p> <p>Another meta‐analysis based on six studies did not find an association between fertility treatment and risk of uterine cancer (<a href="./references#CD010931-bbs2-0058" title="SasoS , LouisLS , DoctorF , HamedAH , ChatterjeeJ , YazbekJ , et al. Does fertility treatment increase the risk of uterine cancer? A meta‐analysis. European Journal of Obstetrics, Gynecolgy and Reproductive Biology2015;195:52‐60. ">Saso 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010931-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA Flow Diagram" data-id="CD010931-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA Flow Diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010931-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010931-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Exposure to any drug; comparison group: subfertile; any, outcome: 2.1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Exposure to any drug; comparison group: subfertile; any, outcome: 2.1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Exposure to any drug; comparison group: general population; any, outcome: 6.1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Exposure to any drug; comparison group: subfertile; any, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Exposure to any drug; comparison group: subfertile; any, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Exposure to any drug; comparison group: subfertile; parous women, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Exposure to any drug; comparison group: subfertile; parous women, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Exposure to any drug; comparison group: subfertile; nulliparous women, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Exposure to any drug; comparison group: subfertile; nulliparous women, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Exposure to any drug; comparison group: subfertile; low number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Exposure to any drug; comparison group: subfertile; low number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Exposure to any drug; comparison group: subfertile; medium number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Exposure to any drug; comparison group: subfertile; medium number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-006-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Exposure to any drug; comparison group: general population; any, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Exposure to any drug; comparison group: general population; any, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Exposure to any drug; comparison group: general population; low number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Exposure to any drug; comparison group: general population; low number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Exposure to any drug; comparison group: general population; medium number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Exposure to any drug; comparison group: general population; medium number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Exposure to any drug; comparison group: general population; 0‐3 number of oocytes retrieved, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Exposure to any drug; comparison group: general population; 0‐3 number of oocytes retrieved, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Exposure to any drug; comparison group: general population; &gt;10 number of oocytes retrieved, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Exposure to any drug; comparison group: general population; &gt;10 number of oocytes retrieved, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Exposure to clomiphene; comparison group: subfertile: any, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Exposure to clomiphene; comparison group: subfertile: any, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Exposure to clomiphene; comparison group: subfertile; low dosage, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Exposure to clomiphene; comparison group: subfertile; low dosage, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Exposure to clomiphene; comparison group: subfertile; medium dosage, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Exposure to clomiphene; comparison group: subfertile; medium dosage, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Exposure to clomiphene; comparison group: subfertile; high dosage, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Exposure to clomiphene; comparison group: subfertile; high dosage, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Exposure to clomiphene; comparison group: subfertile; medium number of cycles, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Exposure to clomiphene; comparison group: subfertile; medium number of cycles, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Exposure to clomiphene; comparison group: subfertile; high number of cycles, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Exposure to clomiphene; comparison group: subfertile; high number of cycles, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Exposure to clomiphene; comparison group: subfertile: parous women, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Exposure to clomiphene; comparison group: subfertile: parous women, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Exposure to clomiphene; comparison group: subfertile; nulliparous women, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Exposure to clomiphene; comparison group: subfertile; nulliparous women, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Exposure to clomiphene; comparison group: general population; any, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Exposure to clomiphene; comparison group: general population; any, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Exposure to clomiphene; comparison group: general population; low dosage, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Exposure to clomiphene; comparison group: general population; low dosage, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Exposure to clomiphene; comparison group: general population; high dosage, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Exposure to clomiphene; comparison group: general population; high dosage, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Exposure to clomiphene; comparison group: general population; low number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Exposure to clomiphene; comparison group: general population; low number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Exposure to clomiphene; comparison group: general population; high number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Exposure to clomiphene; comparison group: general population; high number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Exposure to gonadotropins; comparison group: subfertile; any, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Exposure to gonadotropins; comparison group: subfertile; any, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Exposure to gonadotropins; comparison group: subfertile; medium number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 Exposure to gonadotropins; comparison group: subfertile; medium number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Exposure to gonadotropins; comparison group: subfertile; high number of cycles, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 Exposure to gonadotropins; comparison group: subfertile; high number of cycles, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Exposure to gonadotropins; comparison group: general population; any, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 Exposure to gonadotropins; comparison group: general population; any, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-028-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-028-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Exposure to clomiphene + gonadotropins; comparison group: subfertile; any, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-028-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28 Exposure to clomiphene + gonadotropins; comparison group: subfertile; any, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-028-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-029-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-029-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Exposure to clomiphene + gonadotropins; comparison group: general population; any, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-029-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29 Exposure to clomiphene + gonadotropins; comparison group: general population; any, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-029-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-030-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-030-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Exposure to GnRH; comparison group: subfertile; any, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-030-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30 Exposure to GnRH; comparison group: subfertile; any, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-030-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-031-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-031-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Exposure to GnRH; comparison group: subfertile; parous women, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-031-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31 Exposure to GnRH; comparison group: subfertile; parous women, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-031-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-032-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-032-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 Exposure to GnRH; comparison group: subfertile; nulliparous women, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-032-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32 Exposure to GnRH; comparison group: subfertile; nulliparous women, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-032-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-033-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-033-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 33 Exposure to any drug; comparison group: subfertile; any; follow‐up &gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-033-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33 Exposure to any drug; comparison group: subfertile; any; follow‐up &gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-033-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-034-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-034-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Exposure to any drug; comparison group: general population; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-034-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34 Exposure to any drug; comparison group: general population; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-034-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-035-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-035-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 35 Exposure to clomiphene; comparison group: subfertile; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-035-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.1</div> <div class="figure-caption"> <p>Comparison 35 Exposure to clomiphene; comparison group: subfertile; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-035-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-036-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-036-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 36 Exposure to clomiphene; comparison group: general population; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-036-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.1</div> <div class="figure-caption"> <p>Comparison 36 Exposure to clomiphene; comparison group: general population; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-036-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-037-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-037-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Exposure to gonadotropins; comparison group: subfertile; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate." data-id="CD010931-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-037-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.1</div> <div class="figure-caption"> <p>Comparison 37 Exposure to gonadotropins; comparison group: subfertile; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer; subgroup by effect estimate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-037-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010931-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/urn:x-wiley:14651858:media:CD010931:CD010931-CMP-038-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_t/tCD010931-CMP-038-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 38 Exposure to clomiphene + gonadotropins; comparison group: general population; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer." data-id="CD010931-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-038-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.1</div> <div class="figure-caption"> <p>Comparison 38 Exposure to clomiphene + gonadotropins; comparison group: general population; any; follow‐up&gt;10 years, Outcome 1 Endometrial cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/media/CDSR/CD010931/image_n/nCD010931-CMP-038-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Exposure to any ovary‐stimulating drugs for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to any ovary‐stimulating drug for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to any ovary‐stimulating drug for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.67 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>156,774<br/> (6 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 100,000<br/> (74 to 163) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of high risk of bias.<br/> <sup>3</sup>Optimal information size (OIS) criterion not met (OIS = 499,938); however, the sample size was large. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Exposure to any ovary‐stimulating drugs for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Exposure to any ovary‐stimulating drugs for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to any ovary‐stimulating drug for subfertility<br/> <b>Comparison:</b> General population </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to any ovary‐stimulating drug for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75<br/> (1.18 to 2.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1,762,829<br/> (15 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>92 per 100,000<br/> (62 to 138) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of high risk of bias.<br/> <sup>3</sup> Downgraded due to inconsistency of results (significant heterogeneity) and imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Exposure to any ovary‐stimulating drugs for subfertility compared to general population and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Exposure to clomiphene citrate for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/> (1.01 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92,849<br/> (5 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>524 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>691 per 100,000<br/> (530 to 894) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup> Optimal information size (OIS) criterion not met; however, the sample size was large. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Exposure to clomiphene citrate for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Exposure to clomiphene citrate for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate for subfertility<br/> <b>Comparison:</b> General population </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.87<br/> (1.00 to 3.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,614<br/> (4 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>529 per 100,000<br/> (284 to 980) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup>Optimal information size (OIS) criterion not met. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Exposure to clomiphene citrate for subfertility compared to general population and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Exposure to gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>undefined</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to gonadotropins for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.55<br/> (1.03 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>17,769<br/> (4 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1291 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1987 per 100,000<br/> (1329 to 2970) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias in most studies and imprecise estimates in one study.<br/> <sup>3</sup> Optimal information size (OIS) not met. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Exposure to gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Exposure to gonadotropins for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to gonadotropins for subfertility<br/> <b>Comparison:</b> General population </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.12<br/> (0.79 to 5.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1595<br/> (2 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1148 per 100,000<br/> (428 to 3054) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup>Downgraded because of risk of bias and imprecision.<br/> <sup>3</sup> Optimal information size (OIS) not met. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Exposure to gonadotropins for subfertility compared to general population and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Exposure to clomiphene citrate and gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate and gonadotropins for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate and gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/> (0.57 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6345<br/> (2 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>579 per 100,000<br/> (279 to 1196) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup> Optimal information size (OIS) criterion not met. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Exposure to clomiphene citrate and gonadotropins for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Exposure to clomiphene citrate and gonadotropins for subfertility compared to general population and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to clomiphene citrate and gonadotropins for subfertility<br/> <b>Comparison:</b> General population 2.99 [1.53, 5.86] </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to clomiphene citrate and gonadotropins for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.99<br/> (1.53 to 5.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7789<br/> (3 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>245 per 100,000<br/> (150 to 401) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup> Optimal information size (OIS) not met; however, the sample size was large. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Exposure to clomiphene citrate and gonadotropins for subfertility compared to general population and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010931-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Exposure to GnRH analogues for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women treated with ovary‐stimulating drugs for subfertility<br/> <b>Intervention:</b> Exposure to GnRH analogues for subfertility<br/> <b>Comparison:</b> Untreated subfertile women </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with exposure to GnRH analogs for subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endometrial cancer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.21<br/> (0.65 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>42,558<br/> (2 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 100,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>554 per 100,000<br/> (297 to 1039) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Initial level of evidence was 'low' because of the study design (observational studies).<br/> <sup>2</sup> Downgraded because of risk of bias.<br/> <sup>3</sup>Optimal information size (OIS) criterion not met; however, the sample size was large </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Exposure to GnRH analogues for subfertility compared to untreated subfertile women and endometrial cancer risk</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/full#CD010931-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.67, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.61, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 IRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.46, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.52, 1.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; parous women</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.05, 18.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; parous women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; nulliparous women</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.35, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; nulliparous women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; low number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.11, 6.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; low number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; medium number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.46, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; medium number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Exposure to any drug; comparison group: general population; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1.762829E6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.18, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SIR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.92, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.96, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 IRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>647704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.11, 25.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>821278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.32, 7.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [1.67, 7.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Exposure to any drug; comparison group: general population; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Exposure to any drug; comparison group: general population; low number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.93, 5.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Exposure to any drug; comparison group: general population; low number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Exposure to any drug; comparison group: general population; medium number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [0.77, 14.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Exposure to any drug; comparison group: general population; medium number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Exposure to any drug; comparison group: general population; 0‐3 number of oocytes retrieved</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.47, 18.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Exposure to any drug; comparison group: general population; 0‐3 number of oocytes retrieved</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Exposure to any drug; comparison group: general population; &gt;10 number of oocytes retrieved</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.93 [2.24, 21.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Exposure to any drug; comparison group: general population; &gt;10 number of oocytes retrieved</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile: any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.01, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.94, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.88, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 IRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.38, 2.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile: any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; low dosage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.78, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; low dosage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; medium dosage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.76, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; medium dosage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; high dosage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.07, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; high dosage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; medium number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.87, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.61, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.85, 2.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; medium number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; high number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.16, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.08, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.95, 2.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; high number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile: parous women</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.82, 3.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile: parous women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; nulliparous women</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.51, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; nulliparous women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.00, 3.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SIR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.79, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.24, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [1.56, 13.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; low dosage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.48, 4.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; low dosage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; high dosage</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.48 [2.28, 13.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; high dosage</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; low number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.56, 5.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; low number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; high number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.17 [1.35, 12.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; high number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.03, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.11, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 IRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.28, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.76, 2.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; medium number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.00, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; medium number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; high number of cycles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.80, 4.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; high number of cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Exposure to gonadotropins; comparison group: general population; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.79, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Exposure to gonadotropins; comparison group: general population; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Exposure to clomiphene + gonadotropins; comparison group: subfertile; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.57, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Exposure to clomiphene + gonadotropins; comparison group: subfertile; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Exposure to clomiphene + gonadotropins; comparison group: general population; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.99 [1.53, 5.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Exposure to clomiphene + gonadotropins; comparison group: general population; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Exposure to GnRH; comparison group: subfertile; any</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.65, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Exposure to GnRH; comparison group: subfertile; any</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Exposure to GnRH; comparison group: subfertile; parous women</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [0.95, 8.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Exposure to GnRH; comparison group: subfertile; parous women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Exposure to GnRH; comparison group: subfertile; nulliparous women</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.34, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Exposure to GnRH; comparison group: subfertile; nulliparous women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0042"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; any; follow‐up &gt;10 years</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.63, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.61, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 IRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.49, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.36, 1.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Exposure to any drug; comparison group: subfertile; any; follow‐up &gt;10 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0043"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Exposure to any drug; comparison group: general population; any; follow‐up&gt;10 years</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [1.80, 3.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SIR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.44, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [1.28, 8.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [1.67, 7.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Exposure to any drug; comparison group: general population; any; follow‐up&gt;10 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0044"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; any; follow‐up&gt;10 years</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.03, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.96, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.88, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 IRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.38, 2.63]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Exposure to clomiphene; comparison group: subfertile; any; follow‐up&gt;10 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0045"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; any; follow‐up&gt;10 years</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [1.01, 4.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SIR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.79, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [1.56, 13.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Exposure to clomiphene; comparison group: general population; any; follow‐up&gt;10 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0046"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; any; follow‐up&gt;10 years</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer; subgroup by effect estimate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7937</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.01, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 RR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.11, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 IRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.28, 3.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Exposure to gonadotropins; comparison group: subfertile; any; follow‐up&gt;10 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010931-tbl-0047"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">Exposure to clomiphene + gonadotropins; comparison group: general population; any; follow‐up&gt;10 years</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Endometrial cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [1.82, 7.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">Exposure to clomiphene + gonadotropins; comparison group: general population; any; follow‐up&gt;10 years</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010931.pub2/references#CD010931-tbl-0047">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010931.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010931-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010931-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010931-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010931-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010931-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010931-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010931-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010931\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010931\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010931\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010931\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010931\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010931.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010931.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010931.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010931.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010931.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729631305"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010931.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729631308"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010931.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee19d0c109377',t:'MTc0MDcyOTYzMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 